<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
	<title>Factiva</title>
<style type="text/css">body{margin:0;}form{margin:0;padding:0;}.icon a{display:block;}.nlFooter .icon a{display:inline-block!important;top:3px;}.icon span{display:none;}#postProcessingNav .icon{margin-right:15px;}#viewSelected,#viewSelected a{width:22px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:0 -212px;}#rtf,#rtf a{width:24px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-23px -212px;}#email,#email a{width:19px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-48px -212px;}#print,#print a{width:18px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-68px -212px;}#save,#save a{width:17px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-87px -212px;}#briefcase,#briefcase a{width:17px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-105px -212px;}#csv,#csv a{width:27px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-125px -212px;}.modalNavGreen{background-color:#9C0;}.modalNavGreen td{vertical-align:middle;height:22px;padding:0 5px;white-space:nowrap;}td.modalTabGreen{height:18px;padding:0 10px 0 5px;vertical-align:bottom;background : url('../img/edgew.gif?42.27.0')  no-repeat right bottom;}td.modalTabWhite{background-color:#fff;height:18px;width:100%;padding:0;}span.tabTitle{color:#333;font-weight:bold;}a.supportLink{color:#55B0EB!important;float:right;vertical-align:top;text-decoration:none;}a.supportLink #helpIconCont{vertical-align:middle;width:19px;height:19px;}.modalSubTitle{position:relative;float:left;top:2px;margin-left:5px;}.modalTitle{position:relative;float:left;}.pipe{font-weight:normal;font-size:10px;color:#B5BACE;}span.checked{color:#A52A2A;font-weight:bold;}DIV.modalForm{background-color:#EEE;margin:10px 10px;}DIV.modalGgoup{width:auto;padding:10px;background-color:#D9DBE8;border-bottom:solid 1px #fff;border-top:solid 1px #fff;}DIV.modalGroupSpace{padding:3px;}.modalContainer{background-color:#EEE;padding:0 10px;}p.button-row{text-align:right;padding:0 10px;}.folderOpen .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -135px -110px transparent;width:21px;height:16px;margin-right:8px;float:left;}.folderClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -134px -94px transparent;width:18px;height:15px;margin-right:11px;float:left;}.groupOpen{padding:3px 0 3px 25px;background : url('../img/group_open.gif?42.27.0')  no-repeat left center;}.groupClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -85px -110px transparent;width:18px;height:15px;margin-right:11px;float:left;}.groupUnknown .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -182px -94px transparent;width:18px;height:14px;margin-right:11px;float:left;}.sharedOpen .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -153px -94px transparent;width:26px;height:15px;margin-right:3px;float:left;}.sharedClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -104px -110px transparent;width:26px;height:15px;margin-right:3px;float:left;}.folderTrigger .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat 0 -110px;width:16px;height:16px;margin-right:13px;float:left;}.folderClosed .itemText,.folderOpen .itemText,.groupClosed .itemText,.groupUnknown .itemText,.sharedOpen .itemText,.sharedClosed .itemText,.folderTrigger .itemText{margin-top:2px;float:left;}.folderClosed,.folderOpen,.groupClosed,.groupUnknown,.sharedOpen,.sharedClosed,.folderTrigger{margin:1px 0;}#folderDD .folderOpen,#folderList .folderOpen{padding-left:3px;}#folderDD .folderClosed,#folderList .folderClosed{padding-left:3px;height:inherit!important;}#folderDD .groupOpen,#folderList .groupOpen{padding-left:3px;}#folderDD .groupClosed,#folderList .groupClosed{padding-left:3px;}#folderDD .groupUnknown,#folderList .groupUnknown{padding-left:3px;}#folderDD .sharedOpen,#folderList .sharedOpen{padding-left:3px;}#folderDD .sharedClosed,#folderList .sharedClosed{padding-left:3px;}#folderDD .folderTrigger,#folderList .folderTrigger{padding-left:3px;}a.folderLink{color:#309;text-decoration:none;}a.folderLink:hover{color:#309;text-decoration:underline;}.onlineUBody{font-style:normal;font-weight:normal;}.padder{text-align:left;background-color:#DCDADA;}.spanheader{float:left;font-weight:bold;width:190px;}.spanheader2{float:left;text-align:right;font-weight:normal;width:auto;}.bol{font-weight:bold;}.padLks{width:100%;text-align:right;}table.usageHeader{background-color:#ffc;margin-top:.5em;padding:0 .5em;border:1px solid black;width:100%;}table.usageHeader th{text-align:left;}table.usageItems{background-color:#eee;border-bottom:2px solid #ccc;border-left:2px solid #ccc;border-right:2px solid #ccc;border-top:2px solid #ccc;width:100%;}table.usageItems thead tr td{background-color:#eee;font-weight:bold;padding-left:5px;color:#000;padding-bottom:0;padding-top:0;text-align:left;}table.usageItems tr,table.usageItems td{background-color:#fff;padding:15px;padding-bottom:0;padding-top:0;text-align:right;}table.usageItems td.first{text-align:left;width:33%;}table.usageItems th{text-align:right;font-weight:bold;}table.usageItems th.first{text-align:left;}table.usageItems tr.even td{background-color:#ffc;}table.usageItems th.whatIf,table.usageItems td.whatIf{color:#060;}table.usageItems tr.footer td{font-weight:bold;background-color:#eee;text-align:right;}table.usageItems tfoot td{font-weight:bold;background-color:#eee;text-align:right;color:#C06;}.APDATA{background-color:#ccc;margin-bottom:0;font-weight:bold;padding:4px;text-align:left;color:#000;}div.last{text-align:right;font-weight:bold;}.bold{font-weight:bold;vertical-align:top;white-space:nowrap;}.greenTable{border:1px solid #BD5;width:100%;}.applyBackGround{background-color:#BD5;}A.simpleLink{color:#000!important;background-color:transparent!important;font-weight:bold!important;}#narrowicon{width:16px;height:10px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -216px -62px;}#wideicon{width:16px;height:10px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -232px -62px;}td.nrCol div a{display:inline-block;height:5px;margin:5px 0 0 5px;width:10px;overflow:hidden;}#uparrow{width:10px;height:5px;display:inline-block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -177px -67px;}#downarrow{width:10px;height:5px;display:inline-block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -177px -60px;}input.majorButton{background-color:#9C0;}input.minorButton{background-color:#CCC;}.errMsg{color:Red;}div.divFactivaException,div.divFactivaException table{background-color:#CCC;}div.divFactivaException table.subTable{background-color:#999;}div.loadingDiv{padding:10px 10px;text-align:center;font-weight:normal;}.colorLinks{color:Blue;}#listenArticle_link{margin:0 0 0 20px;}#cr_span{position:relative;float:left;clear:both;}#crIcon{position:relative;vertical-align:text-top;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -220px -21px;}.relInfoDiv{position:absolute;visibility:hidden;z-index:10000;border:solid 2px #999;border-top-color:#DEDEE9;border-left-color:#DEDEE9;background-color:#FBFBFE;width:450px;overflow:auto;height:auto;}.relInfo div.relInfoHeader{color:#666;padding:5px;border-bottom:solid 1px #DEDEE9;text-align:center;font-weight:bold;}.relInfo div.relInfoSubHeader{padding:5px;font-weight:bold;}.relInfo div.newLine{padding:0 5px 5px 5px;}.relInfo div.newLine a,.relInfo div.newLine a:visited{color:#54559B;text-decoration:none;}.relInfo div.newLine a:hover{text-decoration:underline;}#relInfoBody{padding:10px;}.popupCnt{background-color:#F2F3FB;position:absolute;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}.popupHdr{clear:both;background-color:#CCC;vertical-align:middle;padding:5px;height:15px;}div.floatRight{float:right;clear:right;}div.floatLeft{float:left;clear:left;}.popupHdr a.close{color:#309;text-decoration:none;}.popupHdr a.close:hover{color:#309;text-decoration:underline;}.dedupDiv{display:inline;white-space:nowrap;}.dedupDropdown{display:inline-block;white-space:nowrap;vertical-align:top;background:#dee3f1;color:#333;padding:0 0 3px 0;cursor:pointer;border:1px solid;border-top-color:#e9eefb;border-right-color:#99a3c3;border-bottom-color:#99a3c3;border-left-color:#e9eefb;}.dedupDropdown:hover{border-color:#B5BACE;text-decoration:none;}.dedupDropdown span{float:left;margin-left:4px;}.dedupDropdown .ddArrow{display:block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -244px -195px;width:18px;height:14px;}.newIcon{vertical-align:middle;border:none;}.dedupMenu{display:none;position:absolute;z-index:10000;border:1px solid #999;background-color:#f5f6fb;width:360px;}.dedupMenu ul{list-style:none;margin:0;padding:0;text-align:left;}.dedupMenu li a{margin:0;padding:5px;cursor:pointer;display:block;text-decoration:none;outline:none;color:#000;white-space:normal;}.dedupMenu li a:hover{background-color:#C3C4FC;text-decoration:none;}.dedupMenu li.dedupSelected a{background-color:#DFDFFC!important;}#dedupState{font-weight:bold;vertical-align:top;}#dedupState2{font-weight:bold;}#hlpBox{background-color:#F2F3FB;position:absolute;width:400px;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}#ShowLatestBox{background-color:#F2F3FB;position:absolute;width:500px;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}#hlpBoxShim,#dedupMenuShim{position:absolute;visibility:hidden;left:0;top:0;}.srchHelp{padding:10px;}.srchHelp DIV{padding-bottom:5px;}.srchHelp OL,.srchHelp UL{margin-top:2px;}.srchHelp .OL{list-style-type:decimal;}.hplTable{padding:10px;overflow:hidden;}.hplTable table td{white-space:normal;}.BoxTL{padding-left:0;margin-right:1px;}.BoxTL .BoxTR{background-color:#E2E6F3;border:1px solid #8C92B1;padding-top:6px;}.BoxTL .BoxBR{padding-right:6px;}.BoxTL .BoxBL{padding:0 0 6px 6px;}input.majorBtn{background-color:#9C0;}.inputAlign{vertical-align:middle;}.xDialog{position:absolute;top:0;left:0;padding:1px;}.xDialog .header{clear:both;background-color:#CCC;vertical-align:middle;padding:5px;height:15px;color:#333;background:#FFF;font-weight:bold;background : url('../img/nlPopupTabBG.gif?42.27.0')  repeat-x right bottom;}.xDialog .header .close{position:absolute;display:block;top:3px;right:3px;overflow:hidden;}.xDialog .footer{position:relative;background-color:#FFF;padding:3px;}.xDialog .body{position:relative;position:relative;border-top:solid 1px #CCC;background-color:#FFF;height:auto;width:100%;}.xDialog .body .loading{background-color:#FFF;padding:3px;color:#333;font-weight:bold;}.PopupBackground{position:absolute;left:0;top:0;background:#A5A5A5;filter:alpha(opacity=60);opacity:.60;z-index:9999;}#appendAJAX{position:absolute;top:0;left:0;z-index:1000;}.mcemailPopupDialog{position:absolute;top:0;left:0;padding:1px;background : url('../img/mcemailpopupbg.png?42.27.0')  no-repeat left top;}.mobileCookieEmailDiv{position:relative;width:auto;display:block;padding:10px;height:150px;}.mobileCookieEmailDivPlaceholder{position:relative;width:auto;}#mobileCookieEmailDivPopup .buttons .btn{position:static!important;}#mobileCookieEmailDivHeader{font-weight:bold;}#mobileCookieEmailDivMsg3{position:relative;padding:10px;margin-left:70%;white-space:nowrap!important;}#mobileCookieEmailDivPopup{position:relative;margin-right:150px;}#mobileCookieEmailOnClickDiv{display:none;position:relative;vertical-align:top;margin-right:100px;}.odeMessage{color:#CE009C;font-weight:bold;}.edTableRowSeperator{background-color:#CCC;padding-top:1px;padding-bottom:1px;}.edLink{text-decoration:none;color:#648CAF;}.edLink:hover{text-decoration:none;color:#648CAF;}.edLinkPipe{font-family:Arial,Helvetica,sans-serif;color:#999;text-decoration:none;font-weight:normal;}.edTitleBold{font-weight:bold;}.edDescriptionSeperator{background-color:#999;padding-top:2px;padding-bottom:2px;}#translateArticleDiv{display:inline;}#translateArticleDiv a{color:#7C7EC9;text-decoration:none;}#translateArticleDiv img{padding-right:3px;margin-bottom:-2px;border:0;}#translateLanguagesDiv{display:none;position:absolute;border:solid 1px #999;z-index:1;}#translateLanguagesDiv.visiblek{display:inline;}#translateLanguagesDiv ul{list-style-type:none;list-style-position:outside;list-style-image:none;}.languagesDiv{background-color:#FBFBFE;border-color:#DEDEE9 #999999 #999 #DEDEE9;border-style:solid;border-width:2px;height:auto;overflow:auto;position:absolute;visibility:hidden;width:250px;z-index:10000;}#translateLanguagesDiv a,.languagesDiv #relInfoBody a{color:#000;background-color:#F0F0F0;padding-left:5px;padding-right:5px;display:block;}#translateLanguagesDiv a:hover,.languagesDiv #relInfoBody a:hover{background-color:#CCC;}.smb{height:44px!important;}#gl-navTopLeft-ADVISOR{position:absolute;top:0;left:0;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat 0 -21px;width:215px;white-space:nowrap;}#djr1{position:absolute;right:5px;top:46px;width:183px;height:22px;background:#fff url(../img/djr-shadow.gif) no-repeat right top;z-index:9997;}#gl-navTopRightUl li#mbrightddtbm3 DIV{width:220px;}#gl-navTopRightUl li#mbrightddtbm3 ul,#gl-navTopRightUl li#mbrightddtbm3 ul li,#gl-navTopRightUl li#mbrightddtbm3 ul a{width:148px;width:200px;}#gl-navBottomMiddle ul li ul li div,#gl-navBottomMiddle ul li ul li div span{float:left;float:none;}#gl-navBottom div.gl-navBottomHolder{height:1px;font-size:.1em;}#gl-navBottomMiddle li.subMenuSpcr div{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -130px -94px;height:13px;width:1px;margin:0 2px;}#gl-navBottomMiddle li.subMenuSpcr div.EUPipe3{background:none;padding-right:6px;width:0;margin:0;}#gl-navBottomMiddle SPAN.fceSubMenuLabel{padding-left:5px;}#supportGreenLink{background : url('../img/dotcomgreen2.jpg?42.27.0')  no-repeat right top;padding:0 0 5px 0;height:19px;}#supportGreenLink a{color:#369;font-weight:bold;text-decoration:none;background : url('../img/dotcomgreen1.jpg?42.27.0')  no-repeat left top;padding:1px 6px 6px 6px;height:19px;}#supportGreenLink a:hover{color:#369;text-decoration:none;font-weight:bold;}td.supportGreenLink{vertical-align:top;height:22px;padding:0 5px;white-space:nowrap;padding-top:2px;}.feedBack{font-family:Arial,Helvetica,sans-serif;}.footerBG #djInsiderCtrl{display:inline;}#LinkFormExElem{display:none;}#NavAdPlaceHolder{position:absolute;top:6px;right:5px;height:18px;width:155px;font-weight:bold;text-align:center;vertical-align:middle;padding-top:1px;font-family:Arial,Helvetica,sans-serif;}#NavAdPlaceHolder a{color:#005596;}#uiVersion{color:#FFF;}#djimenu{margin:1px 0 0 0;padding:0;height:16px;}#djimenu img{border:none;vertical-align:top;margin-top:-2px;padding-right:8px;}#djimenu a{color:#000;font-weight:bold;text-decoration:none;height:16px;margin:0;padding:0 8px 0 0;font-family:Arial,Helvetica,sans-serif;}.mrm #gl-navBottom{background : url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x scroll 0 0 transparent!important;height:33px;padding:0 0 30px;position:relative;}.mrm #gl-navTopLeft h1{background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -105px transparent!important;width:300px!important;}.mrm #gl-navBottom{background : url('../img/sprite_bg_x_801px.jpg?42.27.0')  repeat-x top left;background-position:0 0;}.insight #gl-navTopLeft h1{background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -135px transparent!important;width:300px!important;background-color:#fff;}html>body #tblinkiff a{padding-top:4px;}.adContainer{position:relative;display:none;padding:0 0 10px 5px;}.adContainer_Login{position:static;display:none;padding:0 0 10px 5px;}.adContainer_Article{position:relative;display:none;padding:0 0 0 5px;}.article_Adwrapper{width:50%;float:right;height:125px;}.adHeader{float:right;}.adBody{clear:both;}a.helpLinkStyle,a.helpLinkStyle:visited{color:#55B0EB;text-decoration:none;cursor:pointer;}a.helpLinkUnderLine,a.helpLinkUnderLine:visited{text-decoration:underline!important;}a.tsLinkStyle,a.tsLinkStyle:visited{color:#800080!important;text-decoration:none;}a.tsLinkUnderLine,a.tsLinkUnderLine:visited{text-decoration:underline!important;}a.tsLinkStyle:hover{color:#800080!important;text-decoration:underline!important;}div.dbgViewXmlFormat{background-color:#000;color:#32cd32;}.brwsLbl{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -250px -73px;}.lkpBar .lkpBtn.wsjLkpBtn{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -241px -21px;}#fiiInstruction{background : url('../img/sprite_bg_x_1px.gif?42.27.0')  repeat-x top left;}#fiiInstruction TD.pnlsTtl div.separator{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -132px -94px;}.tblNav .tblToggleBtn{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -40px transparent;}.tblNav .tblToggleBtn.tblToggleBtnPlus{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -20px transparent;}.firstDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -323px transparent;*display:inline-block;*position:relative;*top:2px;}.secondDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll -2px -343px transparent;}.scheduledDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -382px transparent;}.continuousDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -363px transparent;}.onlineDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -683px transparent;}.emptyDel{background:none;}.xmlLink.xmlLinkWithIcon,.xmlLink.xmlLinkWithIcon a:hover{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -400px transparent!important;}.xmlLinkWithIcon{background : url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat -340px -3px transparent;}.xmlLinkWithIcon:hover{background : url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat -338px -26px transparent;}html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,font,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr{margin:0;padding:0;border:0;outline:0;font-size:100%;background:transparent;font-weight:normal;}.sbTable td{margin:0;padding:0;border:0;outline:0;font-size:100%;background:transparent;font-weight:normal;}body{line-height:1;background-color:#FFF!important;}ol,ul{list-style:none;}blockquote,q{quotes:none;}blockquote:before,blockquote:after,q:before,q:after{content:'';content:none;}select{font-size:1em;padding:1px;}:focus{outline:0;}ins{text-decoration:none;}del{text-decoration:line-through;}table{border-collapse:collapse;border-spacing:0;}body{text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:72.5%;line-height:normal;color:#666;}div,table,td{font-size:1em;}h1,h2,h3,h4,h5,h6{font-size:1em;}p img.left{float:left;margin:1.5em 1.5em 1.5em 0;padding:0;}p img.right{float:right;margin:1.5em 0 1.5em 1.5em;}a{color:#55b0eb;text-decoration:none;}a:focus,a:hover{color:#666;text-decoration:none;}body{margin:0;}#contentWrapper{padding:0 15px;}.WorkSpace .wsList{padding:0!important;}#gl-navContainer{z-index:800;position:relative;width:98%;margin-left:10px;}#gl-navTop{height:33px;background-image:none;background-color:#fff;z-index:810;}#gl-navTop table{height:33px;vertical-align:middle;background-color:#fff;}#gl-navTop table td{vertical-align:middle;}#gl-navTop #gl-navTopLeft{vertical-align:top;padding-left:15px;}#gl-navTop #gl-navTopLeft h1{width:123px;height:20px;font-size:.1em;text-indent:-9999px;background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat 0 -209px #fff;margin:0;padding:0;position:relative;top:6px;}#gl-navTop #gl-navTopRight{padding-right:15px;}#gl-navTopRightUl{float:right;z-index:9997;margin:0;}#gl-navTopRightUl li.userNavItem{float:left;height:12px;position:relative;line-height:12px;padding:0 7px;border-right:1px solid #ccc;z-index:9998;}#gl-navTopRightUl li#mbrightddtbm241{border:none;}#gl-navTopRightUl li a{display:block;line-height:10px;margin-bottom:1px;}#gl-navTopRightUl li a:hover,#gl-navTopRightUl li.over a{color:#55b0eb;}#gl-navTopRightUl li#mbrightddtbm1,#gl-navTopRightUl li#mbrightddtbm0{padding-right:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat right -4px;}#gl-navTopRightUl li#myDJFmenu{background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat left -64px;}#gl-navTopRightUl li.over{background-color:#333;}#gl-navTopRightUl li#mbrightddtbm241{padding-right:6px;}#gl-navTopMiddle a,#gl-navTopRightUl a{color:#666;margin:0;}#gl-navTopRightUl #myDJFmenu a{padding-left:12px;}#gl-navContainer a,#gl-navContainer a:hover{color:#4D5926;text-decoration:none;}#gl-navTopRightUl #mbrightddtbm0 div,#gl-navTopRightUl li .settingsToolsDrop{position:absolute;top:12px;right:0;background-color:#333;padding:5px;border:1px solid #000;z-index:9999;}#gl-navTopRightUl li .settingsToolsDrop{width:450px;_width:452px;}#gl-navTopRightUl li div{display:none;}#gl-navTopRightUl li.over div{display:block;}#gl-navTopRightUl li .settingsToolsDrop div{float:left;width:150px;}#gl-navTopRightUl li .settingsToolsDrop div .sectionTitle{color:#55b0eb;font:normal 1.1em Arial,Helvetica,sans-serif;line-height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 0;margin:0;padding-left:20px;}#gl-navTopRightUl li .settingsToolsDrop div .Tools{background-position:0 -160px;}#gl-navTopRightUl li .settingsToolsDrop div .Lists{background-position:0 -200px;}#gl-navTopRightUl li .settingsToolsDrop div .Language{background-position:0 -240px;}#gl-navTopRightUl li .settingsToolsDrop div .Account{background-position:0 -220px;}#gl-navTopRightUl li .settingsToolsDrop div .Settings{background-position:0 -180px;}#gl-navTopRightUl #mbrightddtbm0 div ul,#gl-navTopRightUl li .settingsToolsDrop div ul{background:none;padding:0;}#gl-navTopRightUl #mbrightddtbm0 div ul{width:250px;}#gl-navTopRightUl li .settingsToolsDrop div ul{margin-bottom:10px;}#gl-navTopRightUl #mbrightddtbm0 div ul li,#gl-navTopRightUl li .settingsToolsDrop div ul li{background:none;border:none;}#gl-navTopRightUl #mbrightddtbm0 div ul li a,#gl-navTopRightUl li .settingsToolsDrop div ul li a{display:block;color:#fff;background:none;padding:3px 20px 3px 10px;white-space:normal;}#gl-navTopRightUl #mbrightddtbm0 div ul li a:hover,#gl-navTopRightUl li .settingsToolsDrop div ul li a:hover{background:none;border:none;color:#333;background-color:#f4f4f4;}#gl-navBottomMiddle ul li.selected ul.selected li.subMenuSpcr{display:none;}#gl-navBottom{height:33px;position:relative;background: transparent url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x 0 0;padding:0 0 30px;}#gl-navBottomMiddle{height:33px;width:100%!important;background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat right -132px;}#gl-navBottomMiddle ul#menulist{height:33px;background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 -99px;padding:0;margin:0;}#gl-navBottomMiddle ul li{float:left;margin:0;padding:0 0 0 15px;cursor:pointer;}#gl-navBottomMiddle ul li.selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 0;}#gl-navBottomMiddle ul li.first-selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 -33px;}#gl-navBottomMiddle ul li a{display:block;float:none;color:#afafaf;cursor:pointer;line-height:33px;background:none;outline:none;padding:0 10px 0 0;}#gl-navBottomMiddle ul li a:hover{color:#afafaf;}#gl-navBottomMiddle ul li.selected a{font-weight:normal;color:#fff;background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -66px;cursor:pointer;}#gl-navBottomMiddle ul li.selected a:hover{color:#fff;}#gl-navBottomMiddle ul li ul{display:none;}#gl-navBottomMiddle ul li.selected ul.selected{display:block;min-width:600px;height:30px;position:absolute;top:33px;left:0;padding:0 15px;cursor:default;}* html #gl-navBottomMiddle ul li.selected ul.selected{width:750px;}#gl-navBottomMiddle ul li.selected ul.selected li{float:left;display:inline-block;height:30px;margin-right:10px;padding:0;white-space:nowrap;}#gl-navBottomMiddle ul li.selected ul.selected li a{display:inline;height:30px;color:#666;line-height:30px;background:none;padding:0;cursor:pointer;}#gl-navBottomMiddle ul li.selected ul.selected li a:hover{color:#55b0eb;}#gl-navBottomMiddle ul li.selected ul.selected li a.selectedSubMenu{color:#55b0eb;font-weight:normal!important;}#mentionedLabel1{z-index:710;}#mentionedLabel1 div{z-index:725;}#pageFooter{background: transparent url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;padding:10px 15px 5px;height:10px;}#pageFooter .shadowL,#pageFooter .shadowR{display:none!important;}.footerBrand{width:101px;background: transparent url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -40px;margin:0;}.ftright{width:66px;background: transparent url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -80px;}#pageFooter .copyright{color:#666;line-height:normal;}.footerBG .feedBack,.feedBack:hover,.footerBG .whatsNew,.whatsNew:hover,.footerBG .privacy,.privacy:hover,.footerBG .djinsider,.djinsider:hover,.footerBG #djInsiderCtrl a,.footerBG #djInsiderCtrl a:hover{color:#666!important;line-height:normal!important;border-right:1px solid #666!important;padding:0 5px!important;}.footerBG .privacy,.privacy:hover{margin-right:10px;border:none;}.footerBG .pipe{display:none;}.simpleSearchBottom:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.simpleSearchBottom,.clearFix{zoom:1;}* html .simpleSearchBottom,* html .clearFix{height:1%;}.clear{clear:both;height:0;overflow:hidden;}.ac_input{font:Arial,Helvetica,sans-serif!important;}.ssTable{width:100%;}.ssTable td{vertical-align:top;}.ssTable .shadowLeft{width:10px;height:20px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  no-repeat 0 0;}.ssTable .ssTextBox{height:26px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  repeat-x 0 -56px;}.ssTable .shadowRight{width:12px;height:20px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  no-repeat 0 -28px;}.ssTable .ssTextBox input{width:100%;mn-height:17px;line-height:13px;background:none;border:none;margin:0;padding-top:6px;outline:none;}.simpleSearchBottom{padding:5px 0;}.simpleSearchSelectSource{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;margin-right:10px;}.simpleSearchSelectDate{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.ssSubmit{float:right;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.ssSubmit ul.buttons{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.columnsCntr ul{list-style:none;}.columnsCntr #LtCol,.columnsCntr #MdCol,.columnsCntr #RtCol{float:left;width:300px;margin-right:30px;}.columnsCntr #RtCol{width:300px;}wHeaderBar{margin-bottom:10px;}.wHeaderTtl span{display:block;color:#007ec5;font:bold 1.6em Arial,Helvetica,sans-serif;padding:0 5px;}.wBodyMax ul li{padding-bottom:3px;}.wBodyMax ul li a{display:block;color:#333;padding:0 5px;}.wBodyMax ul li a:hover{background-color:#f0f0f0;}#dateAndDupRow:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}#dateAndDupRow,.clearFix{zoom:1;}* html #dateAndDupRow,* html .clearFix{height:1%;}.clear{clear:both;height:0;overflow:hidden;}.sbTable{width:100%;}.sbTable .shadowTopLeft{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px 0;}.sbTable .shadowTopMid{height:12px;background: transparent url('../img/facelift/facelift-repeatingBG-sprite2.png?42.27.0')  repeat-x 0 -33px;}.sbTable .shadowTopRight{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -12px;}.sbTable .shadowLeft{width:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  repeat-y 0 0;}.sbTable .sbTextBox{background-color:#fff;}.sbTable .shadowRight{width:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  repeat-y -12px 0;}.sbTable .shadowBotLeft{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -36px;}.sbTable .shadowBotMid{height:12px;background: transparent url('../img/facelift/facelift-repeatingBG-sprite.png?42.27.0')  repeat-x 0 -45px;}.sbTable .shadowBotRight{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -24px;}.sbTable .sbTextBox .searchBuilder{width:100%;background:none;border:none;margin:0;outline:none;font:Arial,Helvetica,sans-serif!important;}.blur{color:#ccc;}.txtWrapperDiv{background:#fff url(../img/facelift/shadowRepeating.png) repeat-x 0 bottom;}.txtWrapperDiv div.shadowL,.txtWrapperDiv div.shadowR{height:20px;}.txtWrapperDiv div.shadowL{background : url('../img/facelift/shadowLeft.png?42.27.0')  no-repeat 0 0;}.txtWrapperDiv div.shadowR{background : url('../img/facelift/shadowRight.png?42.27.0')  no-repeat right 0;}.searchFormDiv td input{width:80%;}.searchToggleSwitchWrap{padding:0 15px;}.freeTextSwitch{border-bottom:1px solid #fff;border-top:1px solid #fff;}.searchFormSwitch{border-bottom:1px solid #fff;}.freeTextSwitch a,.searchFormSwitch a{display:block;color:#666;text-decoration:none;padding:5px 10px;}.freeTextSwitch a:hover,.searchFormSwitch a:hover{text-decoration:none;}.selected a{color:#55b0eb;cursor:default;}.selected a:hover{cursor:default;}.searchToggleBoxWrap{background-color:#F0F0F0;border:1px solid #E7E7E7;padding:10px 0 10px 0;}.searchToggleBoxWrap .col1{width:170px;}.searchToggleBoxWrap .col2{margin-left:170px;float:none!important;}#textAndConceptContainer{position:relative;padding:0 10px 0 0;}.sbTableWrap a{display:block;position:absolute;left:-249px;top:60px;color:#666;font:normal .9em Arial,Helvetica,sans-serif;text-decoration:none;}.sbTableWrap a:hover{color:#55b0eb;}.exampleLink{display:none;padding:10px 0 0 11px;}.exampleLink a{color:#666;font:normal .9em Arial,Helvetica,sans-serif;text-decoration:none;}.fcsclose,.fcsopen{display:block;height:20px;font-weight:bold;line-height:20px;background-image : url('../img/facelift/facelift-icon-sprite.png?42.27.0') ;background-repeat:no-repeat;cursor:pointer;padding:0 0 0 20px;}.fcsclose{background-position:0 -119px;}.fcsopen{background-position:0 -140px;}#dateAndDupRow{padding:10px 0 0 0;}#dateAndDupRow .sbFld{float:left;margin-right:20px;padding:0;}#dateAndDupRow #datePnl{float:left;top:-5px;}.sbFld label{margin:0 5px;}.pnlTab{cursor:pointer;padding:0 5px 0 20px;width:175px;vertical-align:top;height:22px;}.pnlTabOpen{cursor:pointer;width:175px;padding:0 5px 0 20px;vertical-align:top;}.pnlTab .pnlTabArrow{float:right;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -20px;}.pnlTabOpen .pnlTabArrow{float:right;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -40px;}.pnlTrTab .pnlLst{border-bottom:1px solid #f0f0f0;}.pnlLbl{padding:15px 10px 0 10px;}.pnlTrTabOpen .pnlLst{border:none;}.lkpBar{padding:10px 0;}.lkpBar .lkpBtn{float:left;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -80px;margin-left:5px;cursor:pointer;}.pnlFrm{padding-bottom:10px;}.pnlMnu{border:1px solid #e7e7e7;}.pnlMnu .mnuHdr,.rsltHdr{color:#666;font:bold 1.2em Arial,Helvetica,sans-serif;padding:0 0 10px;}a.sbIcon{display:-moz-inline-stack;display:inline-block;width:20px;height:10px;position:static;background:none!important;}a.sbIcon img{display:inline!important;}.sbForm .edit{color:#55B0EB;}#moreSearchRootCont #moreOptsWrp{float:left;margin-right:50px;width:50%;}#moreOptsWrp .headlineViewAs{float:left;margin:5px 5px 5px 0;}#moreOptsWrp .headlineViewAs .viewAsMenu{left:0!important;right:auto;}#moreSearchRootCont #adcntrlPnl{float:left;margin-left:10px;}.botButtonWrap{margin:10px 0;}.botButtonWrap .buttons{float:right;}.columnsCntr:after,.botButtonWrap:after,.snapshotthemes:after,#fdtHldContainer:after,#searchBuilderBoxWrap:after,.cd_div_collapse:after,.ctTab:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.columnsCntr,.botButtonWrap,.snapshotthemes,#fdtHldContainer,#searchBuilderBoxWrap,.cd_div_collapse,.ctTab,.clearFix{zoom:1;}* html .columnsCntr,* html .botButtonWrap,* html .snapshotthemes,* html #fdtHldContainer,* html #searchBuilderBoxWrap,* html .cd_div_collapse,* html .ctTab,* html .clearFix{height:1%;}#searchBuilderBoxWrap{padding-top:6px;clear:both;}#headlineTabs{margin:8px 0 0;padding:5px 0 0;background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;z-index:10;top:1px;}#editws span.shadowL,#editws span.shadowR{display:none!important;}span.shadowL{left:-29px;background : url('../img/facelift/shadowLeft.png?42.27.0')  no-repeat 0 0;}span.shadowR{right:-29px;background : url('../img/facelift/shadowRight.png?42.27.0')  no-repeat 0 0;}* html span.shadowR{right:-15px;}#pageFooter .shadowL{left:-15px;}#pageFooter .shadowR{right:-15px;}.ctTab{list-style:none;padding:0 10px 5px;}.ctTab .tabOff,.ctTab .tabOn{margin-right:10px;}.ctTab .tabOff a{color:#666;font-size:1.1em;text-decoration:none;}.ctTab .tabOff a:hover{color:#333;}.ctTab .tabOff a span{margin-left:2px;}.ctTab .tabOn span{color:#55B0EB;font-size:1.1em;}.fdtContainer{float:left;width:241px;}#fdtWrapper{overflow:auto;position:relative;}.cd_header{cursor:move;position:relative;}.cd_export{padding:3px;position:relative;top:0;z-index:3;color:#666;float:right;}.cd_expand{height:20px;width:20px;position:absolute;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -420px transparent;margin:1px 0 0 20px;z-index:998;}* html .cd_expand{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -420px transparent;}.cd_collapse{height:20px;width:20px;position:absolute;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -460px transparent;margin:1px 0 0 20px;z-index:998;}* html .cd_collapse{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -460px transparent;}.cd_headerA{color:#999;text-decoration:none;}.cd .cd_header .cd_export a:hover{text-decoration:underline;}.cd_title{position:relative;font-weight:bold;margin:0;padding:5px 3px 5px 45px;cursor:move;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -659px transparent;}#snapsnapshotthemesContent{padding:0 0 5px 20px;}ul.snapshotthemes{margin:0;padding:0;list-style:none;}ul.snapshotthemes li{float:left;display:inline;margin-right:6px;white-space:nowrap;}ul.snapshotthemes li a{float:left;line-height:20px;text-transform:lowercase;}.newsThemes1 a{font-size:.9em;}.newsThemes3 a{font-size:.9em;}.newsThemes5 a{font-size:1em;}.newsThemes7 a{font-size:1.1em;}.newsThemes9 a{font-size:1.2em;}.newsThemes11 a{font-size:1.3em;}.newsThemes13 a{font-size:1.4em;}.newsThemes15 a{font-size:1.4em;}.newsThemes17 a{font-size:1.5em;}.newsThemes19 a{font-size:1.6em;}#fdtBar{float:left;width:10px;height:100%;cursor:pointer;}.fdtHldContainer #fdtBar{background:#efefef url(../img/facelift/handles-sprite.png) no-repeat 0 center;}.fdtHldContainerOff #fdtBar{background:#EFEFEF url(../img/facelift/handles-sprite.png) no-repeat -10px center;}.quoteRow:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.quoteRow,.clearFix{zoom:1;}* html .quoteRow,* html .clearFix{height:1%;}div.recognition,#appliedFilters{padding:5px 10px;}div.recognition{font-weight:bold;background-color:#ffffe3;}#appliedFilters .filter{font-weight:bold;float:left;}.nofloat{float:none!important;}.DJIIFilterList .beta{float:left;padding-top:2px;padding-right:5px;}#appliedFilters .DJIIFilterList .beta{float:left;padding-top:0!important;padding-right:5px;}#articleFrame #appliedFilters{padding-top:0!important;}#articleFrame #appliedFilters .DJIIFilterList .beta{float:none!important;padding-top:0!important;padding-right:5px;}#newsFilterLst .DJIIFilterList .beta{padding-top:1px!important;}.recognition .suggested a{color:#007ec5;font-weight:bold;}div.quoteRow .quote{display:block;float:left;}div.quoteRow .quoteLinks{display:block;float:left;padding-left:5px;}.quoteLinks a{color:#007ec5;padding:0 5px;border-left:1px solid #666;}.quoteLinks a:hover{text-decoration:underline;}.change-up-new{text-align:right;padding-right:12px;}.change-down-new{text-align:right;padding-right:12px;}#hldContainer{margin:0 0 0 251px;border-left:solid 1px #CCC;}#resultHeader{margin:0 0 0 251px;border-left:solid 1px #CCC;}.splitterContainer{position:relative;overflow:visible;visibility:visible;height:100%;padding:0;background:transparent;border:none;}.clsSplitter{position:absolute;overflow:hidden;visibility:hidden;margin:0;padding:0;border:none;}.clsPane{position:absolute;visibility:visible;margin:0;padding:0;border:none;}.clsPane{overflow:visible;}.clsPane{overflow:auto;}.headlinesView{margin:0!important;overflow-x:hidden;}.headlinesView body.articleView .clsDragBar,body.headlinesView .clsDragBar{visibility:hidden;}.clsDragBar{position:absolute;overflow:hidden;visibility:visible;margin:0;padding:0;background:#CCC;border:none;}#headlineFrame,body.articleView #articleFrame{border-left:solid 3px #EEE;border-right:solid 3px #EEE;border-bottom:solid 3px #EEE;}#articleFrame,#headlineFrame{border:none;}#headlineFrame,body.articleView #articleFrame{border:none;}#hldSplitterBar{background:#EFEFEF url(../img/facelift/handles-sprite.png) no-repeat -20px center;}#headlineFrame{height:100%;overflow:hidden;}body.headlinesView #headlineFrame,body.articleView #articleFrame{float:none;width:auto;display:block;}body.headlinesView #headlineFrame{border-left:solid 1px #FFF;}.headlineHeader{padding:5px 5px 8px 0;background : url('../img/facelift/shadowRepeating2.png?42.27.0')  repeat-x 0 0;}#carryOver .headlineHeader{border:none;}.nextItem{display:-moz-inline-stack;display:inline-block;line-height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat right -540px;padding-right:20px;padding-left:4px;}.previousItem{display:-moz-inline-stack;display:inline-block;line-height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -520px;padding-left:20px;}#dedupSummary{padding:4px 0 0 4px;}#carryOver .headlineHeader span,#carryOver .headlineHeader b,#carryOver .headlineHeader a{display:-moz-inline-stack;display:inline-block;line-height:20px;}#carryOver .headlineHeader #carryOverCount{font-weight:bold;}#carryOverBtn{width:20px;height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -460px;cursor:pointer;}.carryOverOpen #carryOverBtn{background-position:0 -420px;}#carryOver #carryOverBtn span{visibility:hidden;}#carryOverHeadlines{display:none;}.carryOverOpen #carryOverHeadlines{display:block;overflow:auto;border-bottom:1px solid #ccc;}a.carryOverRmv,a.carryOverRmv:visited{color:Red;font-size:14px;font-weight:600;line-height:13px;text-decoration:none;}.saveHeadlines #carryOverHeadlines{display:block!important;}#headlines{overflow:visible;_width:99%;}#headlines{overflow:auto;}.headline a{color:#007EC5;padding-bottom:2px;text-decoration:none;}#headlines a b,.headlines a b,#headlines .caHeadline,#headlines .bgHeadline,#headlines .caHeadline,#headlines .zhtwHeadline,#headlines .zhcnHeadline,#headlines .csHeadline,#headlines .daHeadline,#headlines .nlHeadline,#headlines .enHeadline,#headlines .fiHeadline,#headlines .frHeadline,#headlines .deHeadline,#headlines .huHeadline,#headlines .itHeadline,#headlines .jaHeadline,#headlines .noHeadline,#headlines .plHeadline,#headlines .ptHeadline,#headlines .ruHeadline,#headlines .skHeadline,#headlines .esHeadline,#headlines .svHeadline,#headlines .trHeadline,#headlines .koHeadline,#headlines .idHeadline,#headlines .msHeadline,#headlines .arHeadline{font-weight:bold;}.headline .leadFields{color:#888;font-size:.9em;}.headline .leadFields a{font-weight:normal!important;}.headline .snippet{color:#333;}.enHeadline{font-weight:bold;}.dedupHeadlines{padding:5px 5px 7px;}.mnuBtn,.mnuBtnOpen{color:#666;background-color:#F0F0F0;border:1px solid #D1D1D1;border-right-color:#393939;border-bottom-color:#393939;}.mnuBtn,.mnuBtnOpen{cursor:pointer;}.mnuBtnOpen span{font-size:10px;padding:0 3px;}.mnuBtn span{font-size:10px;padding:0 2px;}body.headlinesView #articleFrame,body.articleView #headlineFrame{float:none;display:none;}#articleFrame{padding:10px;}#articleFrame{border-right:solid 3px #EEE;border-bottom:solid 3px #EEE;}#articleFrame{border:none;}#articleFrame,body.framed #articleFrame,body.articleView #articleFrame{padding:0 1px 5px 2px;}#adFrameDiv{padding-top:20px;text-align:center;}.articleHref{line-height:1px;}.articleHeader{margin:0;padding:0 2px 2px 3px;}.articleHeader{margin:0;padding:7px;background-color:#E4E4E4;}.emg_speaker_button_span{position:relative;margin:0 0 0 5px;}.emg_speaker_attribution_cntr{position:relative;color:#999;}div.article{padding:0 10px;}div.article p{margin:1em 0;}.article #hd{color:#333;font:1.8em Arial,Helvetica,sans-serif;margin-bottom:2px;}.article #hd a{color:#007ec5;}.article .author{color:#333;margin-bottom:5px;}.article .srcLogo{border:0;}.article .articleParagraph{color:#333;margin-top:5px;}.headerTd{background:#efefef;padding:2px;}div.tabcontent{padding:5px 5px 20px;background:#f4fafe;}div.tabcontent td{padding:0 10px 0 0;}#navtab table tr #tabselected,#navtab table tr #tabselected td{background:#f4fafe;}#navtab table tr td table{cursor:pointer;}.menulist{display:-moz-inline-stack;display:inline-block;height:26px;padding:2px 0;float:left;}.menulist li{float:left;display:-moz-inline-stack;display:inline-block;width:26px;margin-right:2px;position:relative;}.menulist li .ppsBtn{display:block;text-indent:-9999px;font-size:.1em;width:26px;height:26px;background: transparent url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat 0 0;}.menulist li.ppsview .ppsBtn{background-position:0 0;}.menulist li.ppsemail .ppsBtn{background-position:-26px 0;}.menulist li.ppsprint .ppsBtn{background-position:-52px 0;}.menulist li.ppssave .ppsBtn{background-position:-78px 0;}.menulist li.ppsbriefcase .ppsBtn{background-position:-104px 0;}.menulist li.ppsrtf .ppsBtn{background-position:-156px 0;}.menulist li.ppspdf .ppsBtn{background-position:-130px 0;}.menulist li.ppsxml .ppsBtn{background-position:-182px 0;}.menulist li.ppsnewsletter .ppsBtn{background-position:-208px 0;}.menulist li.ppsquestion .ppsBtn{background-position:-234px 0;}.menulist li.ppclipboard .ppsBtn{background-position:-312px 0;}.menulist li.ppsdeleteselected .ppsBtn{background-position:-364px 0;}.menulist li.ppsview .ppsBtn:hover{background-position:0 -26px;}.menulist li.ppsemail .ppsBtn:hover{background-position:-26px -26px;}.menulist li.ppsprint .ppsBtn:hover{background-position:-52px -26px;}.menulist li.ppssave .ppsBtn:hover{background-position:-78px -26px;}.menulist li.ppsbriefcase .ppsBtn:hover{background-position:-104px -26px;}.menulist li.ppsrtf .ppsBtn:hover{background-position:-156px -26px;}.menulist li.ppspdf .ppsBtn:hover{background-position:-130px -26px;}.menulist li.ppsxml .ppsBtn:hover{background-position:-182px -26px;}.menulist li.ppsnewsletter .ppsBtn:hover{background-position:-208px -26px;}.menulist li.ppsquestion .ppsBtn:hover{background-position:-234px -26px;}.menulist li.ppclipboard .ppsBtn:hover{background-position:-312px -26px;}.menulist li.ppsdeleteselected .ppsBtn:hover{background-position:-364px -26px;}.menulist li.ppsview .ppsBtn.active:hover,.menulist li.ppsview .ppsBtn.active{background-position:0 -52px;}.menulist li.ppsemail .ppsBtn.active:hover,.menulist li.ppsemail .ppsBtn.active{background-position:-26px -52px;}.menulist li.ppsprint .ppsBtn.active:hover,.menulist li.ppsprint .ppsBtn.active{background-position:-52px -52px;}.menulist li.ppssave .ppsBtn.active:hover,.menulist li.ppssave .ppsBtn.active{background-position:-78px -52px;}.menulist li.ppsbriefcase .ppsBtn.active:hover,.menulist li.ppsbriefcase .ppsBtn.active{background-position:-104px -52px;}.menulist li.ppsrtf .ppsBtn.active:hover,.menulist li.ppsrtf .ppsBtn.active{background-position:-156px -52px;}.menulist li.ppspdf .ppsBtn.active:hover,.menulist li.ppspdf .ppsBtn.active{background-position:-130px -52px;}.menulist li.ppsxml .ppsBtn.active:hover,.menulist li.ppsxml .ppsBtn.active{background-position:-182px -52px;}.menulist li.ppsnewsletter .ppsBtn.active:hover,.menulist li.ppsnewsletter .ppsBtn.active{background-position:-208px -52px;}.menulist li.ppsquestion .ppsBtn.active:hover,.menulist li.ppsquestion .ppsBtn.active{background-position:-234px -52px;}.menulist li.ppclipboard .ppsBtn.active:hover,.menulist li.ppclipboard .ppsBtn.active{background-position:-312px -52px;}.menulist li.ppsdeleteselected .ppsBtn.active:hover,.menulist li.ppsdeleteselected .ppsBtn.active{background-position:-364px -52px;}.menulist li ul{display:none;}.mentionedLabelOff{display:none;}.firstRow{color:#FFF;font:bold 1.2em Arial,Helvetica,sans-serif;background-color:#666!important;padding:8px!important;}.even,.even td{background-color:#efefef;}.odd,.odd td{background-color:#FFF;}#framesLink,#noFramesLink{float:right;display:block;text-indent:-9999px;font-size:.1em;height:26px;width:26px;margin:2px 0 0 2px;background: transparent url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat 0 0;text-decoration:none;}#framesLink{background-position:-260px 0;}#noFramesLink{background-position:-286px 0;}#framesLink:hover{background-position:-260px -26px;text-decoration:none;}#noFramesLink:hover{background-position:-286px -26px;text-decoration:none;}#framesLink.active:hover,#framesLink.active{background-position:-260px -52px;}#noFramesLink.active:hover,#noFramesLink.active{background-position:-286px -52px;}.controlsDiv:after,.frames:after,.actions:after,.resultPagination:after,.postProcessing:after,.presentationToggle:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.controlsDiv,.frames,.actions,.resultPagination,.postProcessing,.presentationToggle,.clearFix{zoom:1;}* html .controlsDiv,* html .frames,* html .actions,* html .resultPagination,* html .postProcessing,* html .presentationToggle,* html .clearFix{height:1%;}.headlineOptions{background-color:#e4e4e4;padding:2px 0;background-color:#e4e4e4;z-index:400;height:36px;}.headlineSort{float:left;display:-moz-inline-stack;display:inline-block;height:20px;vertical-align:middle;padding:5px;}.headlineDups{float:left;display:-moz-inline-stack;display:inline-block;height:20px;vertical-align:middle;padding:5px;}.headlineViewAs{text-align:left;position:relative;display:-moz-inline-stack;display:inline-block;vertical-align:middle;margin:4px 0 0;z-index:405;cursor:pointer;}.headlineViewAs a{display:block;padding:4px;}.headlineOptionsRight .open a,.headlineViewAs a:hover{background-color:#ccc;}.headlineViewAs .viewAs{display:block;padding:0 5px;line-height:20px;}.headlineViewAs .viewAs:hover,.open .viewAs{background-color:#d4d4d4;}.headlineViewAs .viewAsMenu{display:none;width:300px;position:absolute;top:22px;right:0;background-color:#fff;border:1px solid #ccc;z-index:406;}.open .viewAsMenu{display:block;}.headlineViewAs .optionList{height:200px;overflow:auto;background:#fff;z-index:751;}.headlineOptionsRight .open .optionList li a{display:block;padding:2px 5px;background-color:#fff;}* html .headlineOptionsRight .open .optionList li a{display:inline-block;width:100%;}.headlineOptionsRight .open .optionList li a:hover{background-color:#ffffe3;text-decoration:none;}.headlineViewAs .createNewView{margin:0 3px;padding:5px 0;border-top:1px solid #ccc;z-index:751;}.headlineOptionsRight .open .createNewView a{display:inline;color:#666;padding:0;background:none;}.headlineOptionsRight .open .createNewView a:hover{color:#55b0eb;background:none;}.headlineOptions input,.headlineOptions select{line-height:20px;}.buttons:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.buttons,.clearFix{zoom:1;}* html .buttons,* html .clearFix{height:1%;}.buttons{list-style:none;margin:0;padding:0;white-space:nowrap;}.buttons .btn{float:left;position:relative;padding-left:10px;}.buttons .btn .prettyBtn{height:23px;line-height:23px;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;padding-left:11px;cursor:pointer;padding-top:0;padding-bottom:0;}.buttons .btn .prettyBtn span{display:block;height:23px;line-height:23px;color:#fff;background-color:transparent;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;background-repeat:no-repeat;cursor:pointer;}.buttons .btn .prettyBtn{background-position:0 -647px;}.buttons .btn .prettyBtn span{background-position:right -671px;padding:0 15px 0 4px;}.buttons .btn .primaryBtnRight{background-position:0 -257px;}.buttons .btn .primaryBtnRight span{background-position:right -281px;padding:0 22px 0 4px;}.buttons .btn .primaryBtnLeft{background-position:right -744px;padding:0 11px 0 0;}.buttons .btn .primaryBtnLeft span{background-position:0 -768px;padding:0 4px 0 22px;}.buttons .btn .secondaryBtn{background-position:0 -165px;}.buttons .btn .secondaryBtn span{background-position:right -188px;padding:0 15px 0 4px;}.buttons .btn .disabled,.buttons .btn .tertiaryBtn{background-position:0 -353px;}.buttons .btn .disabled{cursor:default;}.buttons .btn .disabled span,.buttons .btn .tertiaryBtn span{color:#999;background-position:right -377px;padding:0 15px 0 4px;}.buttons .btn .disabled span{cursor:default;}.buttons .over .prettyBtn{background-position:0 -695px;}.buttons .over .prettyBtn span{background-position:right -719px;}.buttons .over .primaryBtnRight{background-position:0 -305px;}.buttons .over .primaryBtnRight span{background-position:right -329px;}.buttons .over .primaryBtnLeft{background-position:right -792px;}.buttons .over .primaryBtnLeft span{background-position:0 -816px;}.buttons .over .secondaryBtn{background-position:0 -211px;}.buttons .over .secondaryBtn span{background-position:right -234px;}.buttons .over .tertiaryBtn{background-position:0 -165px;}.buttons .over .tertiaryBtn span{color:#fff;background-position:right -188px;}.buttons .standardBtn{position:absolute;top:0;left:0;right:0;bottom:0;cursor:pointer;}.buttons .standardBtn{opacity:0;filter:alpha(opacity=0);}* html .buttons .btn .prettyBtn{display:inline;}* html .buttons .btn .prettyBtn span{display:inline-block;}ul.floatRight{float:right!important;}.modalHeader:after,.modalFooter:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.modalHeader,.modalFooter,.clearFix{zoom:1;}* html .modalHeader,* html .modalFooter,* html .clearFix{height:1%;}.modal{padding:10px;background-color:#fff;}.modalHeader{padding:10px;background-color:#efefef;}.modalHeader .modalTitle{font-size:1.2em;font-weight:bold;}.modalContent{padding:10px;}.modalFooter{padding:0 10px;}.modalFooter .buttons{float:right;display:-moz-inline-stack;display:inline-block;}#emailModal .modalHeader .supportLink{float:right;display:-moz-inline-stack;display:inline-block;}#emailModal .modalContent .disclaimer{color:#afafaf;margin-bottom:5px;}#emailModal .modalContent .disclaimer a{color:#007ec5;}#emailModal .emailOptions table{width:100%;}#emailModal .emailOptions table td{vertical-align:top;padding:3px;}#emailModal .emailOptions table td .emailUpdate{color:#007ec5;}#emailModal .emailOptions table td.label{text-align:right;}#emailModal .emailOptions table td label{margin:0 5px 0 2px;}.appliedFilters:after,.DJIIFilterList:after,.connectionAndPillWrap:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.appliedFilters,.DJIIFilterList,.connectionAndPillWrap,.clearFix{zoom:1;}* html .appliedFilters,* html .DJIIFilterList,* html .connectionAndPillWrap,* html .clearFix{height:1%;}.pillOptionsList{cursor:pointer;}.filterText{white-space:nowrap;}.DJIIFilterList li{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-bottom:3px;}#ml_sc_edit_selected_list .DJIIFilterList li{clear:left;}#sccompanylist .DJIIFilterList li{clear:left;}.connectionAndPillWrap .filterConnection,.connectionAndPillWrap .filterPillWrap,.connectionAndPillWrap .filterType{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-right:5px;}.DJIIFilterList .pill,.DJIIFilterList .pill .filterText,.DJIIFilterList .pillNoMenu,.DJIIFilterList .pillNoMenu .filterText,.DJIIFilterList .filterConnection,.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .pillOption,.pillOptionsList .pillOption span{background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;background-repeat:no-repeat;}.DJIIFilterList .pill{background-position:0 -402px;}.DJIIFilterList .pill .filterText{background-position:right -419px;}.DJIIFilterList .pillNoMenu{background-position:0 -577px;}.DJIIFilterList .pillNoMenu .filterText{background-position:right -594px;}.DJIIFilterList .filterConnection,.pillOptionsList .or,.pillOptionsList .not,.pillOptionsList .and{background-position:0 -472px;}.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span{background-position:right -489px;}.pillOptionsList .remove{background-position:0 -542px;}.pillOptionsList .remove span{background-position:right -559px;}.DJIIFilterList .pill:hover,.DJIIFilterList .active .pill{background-position:0 -437px;}.DJIIFilterList .pill:hover .filterText,.DJIIFilterList .active .pill .filterText{background-position:right -454px;}.DJIIFilterList .pillNoMenu:hover,.DJIIFilterList .active .pillNoMenu{background-position:0 -612px;}.DJIIFilterList .pillNoMenu:hover .filterText,.DJIIFilterList .active .pillNoMenu .filterText{background-position:right -629px;}.pillOptionsList .or:hover,.pillOptionsList .not:hover,.pillOptionsList .and:hover,.pillOptionsList .remove:hover{background-position:0 -507px;}.pillOptionsList .or:hover span,.pillOptionsList .not:hover span,.pillOptionsList .and:hover span,.pillOptionsList .remove:hover span{color:#fff;background-position:right -524px;}.pillOptionsList .or,.pillOptionsList .not,.pillOptionsList .and,.pillOptionsList .remove{min-width:100px;height:17px;line-height:17px;padding:0 0 0 6px;}* html .pillOptionsList .or,* html .pillOptionsList .not,* html .pillOptionsList .and,* html .pillOptionsList .remove{width:100px;}.DJIIFilterList .pill,.DJIIFilterList .pillNoMenu,.DJIIFilterList .filterConnection{display:-moz-inline-stack;display:inline-block;float:left;height:17px;line-height:17px;padding:0 0 0 6px;}.DJIIFilterList .pill .filterText,.DJIIFilterList .pillNoMenu .filterText,.DJIIFilterList .filterConnection .connectionText,.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span,.pillOptionsList .remove span{display:-moz-inline-stack;display:inline-block;height:17px;color:#333;line-height:17px;text-align:center;padding:0 10px 0 4px;}.connectionTextOr,.connectionTextAnd{cursor:default;}#coLst .connectionTextOr,#coLst .connectionTextAnd,#nsLst .connectionTextOr,#nsLst .connectionTextAnd,#inLst .connectionTextOr,#inLst .connectionTextAnd,#reLst .connectionTextOr,#reLst .connectionTextAnd{cursor:pointer!important;}.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span,.pillOptionsList .remove span{display:block;}.pillOptionsList .remove span{color:#fff;}.DJIIFilterList .pill .filterText{padding:0 20px 0 4px;}.active .pillOptionsList{display:block;position:absolute;top:17px;right:0;}.appliedFilters .label,.appliedFilters .DJIIFilterList{float:left;display:-moz-inline-stack;display:inline-block;margin-right:5px;}.appliedFilters .label{font-weight:bold;}.noFilterTextIn{background-position:right -593px!important;height:30px!important;}.floatLeft{float:left;}.floatRight{float:right;}.headlineOptionsLeft{float:left;display:-moz-inline-stack;display:inline-block;padding:0 0 0 10px;}.headlineOptionsLeft span{float:left;display:-moz-inline-stack;display:inline-block;padding:6px 0 0;margin:0 5px 0 0;}.headlineOptionsRight{float:right;display:-moz-inline-stack;display:inline-block;padding:0 10px 0 0;z-index:403;text-align:right;}.headlineOptionsRight span{position:relative;display:-moz-inline-stack;display:inline-block;z-index:749;margin:4px 0 0;vertical-align:middle;}.headlineOptionsRight span span,.headlineOptionsRight span span span{margin:0;}#mentionedLabel1{z-index:401;}#mentionedLabel1 div{z-index:402;}#mentionedLabel1 .postprocessinglinks{margin:2px 5px 0 5px;padding:0;}.clear{clear:both;}.marginLeft_0px{margin-left:0!important;}.paddingLeft_10px{padding-left:10px!important;}.headlines tr.over{background:#FFFFE3;}#directLinkBox .overlayfooter ul{float:right;}#directLinkBox td{padding:3px;}.overlaycontainer{font-family:Arial,Helvetica,sans-serif;font-size:12px;background:white;border:solid 1px silver;width:600px;margin:20px;position:relative;}.overlayrenamecontainer{font-family:Arial,Helvetica,sans-serif;font-size:12px;background:white;border:solid 1px silver;width:350px;height:120px;margin:20px;position:relative;}.overlayclose{background : url('../img/close.png?42.27.0')  no-repeat;_background : url('../img/close2.gif?42.27.0')  no-repeat!important;cursor:pointer;position:absolute;width:25px;height:25px;right:-15px;top:-15px;}* html .overlayclose{background : url('../img/close.gif?42.27.0')  no-repeat;}.overlayheader{font-family:Arial,Helvetica,sans-serif;font-size:12px;font-weight:bold;margin:10px;background:#4b4b4b;padding:7px;color:#fff;}.overlaybody{margin:10px;}.overlaytable{border-collapse:separate;border-spacing:5px;}.overlaytable td{vertical-align:middle;}.overlaytitle{width:120px;white-space:nowrap;}.overlayselect{border:solid 1px #ccc;width:300px;}.overlaycreatelist{border:solid 1px #ccc;width:296px;}.overlaylink{color:#309;cursor:pointer;padding-left:5px;padding-right:5px;}.overlaylinkdisable{color:#ccc;cursor:none;}.overlayline{margin-top:5px;margin-bottom:15px;border:solid 1px #ccc;}.overlaytext{border:solid 1px #ccc;width:300px;}.overlaysourcelist{height:160px;overflow:auto;}.overlayitem{border:solid 1px #FBE0A8;background:#FBE0A8;padding:2px 5px 2px 5px;margin-bottom:2px;}.overlayfooter{margin:10px;}.overlaytextbold{font-weight:bold;}.ceprogress{display:none;background-color:#fff;border:1px outset #ccc;font-family:Arial,Helvetica,sans-serif;font-size:11px;color:#000;-webkit-border-radius:3px;-moz-border-radius:3px;position:absolute;z-index:10006;width:140px;text-align:center;padding:5px;}.ceerror{color:#f00;}.overlaypillscontextmenu{position:absolute;display:none;z-index:10002;}#directLinkBox .overlayfooter{position:relative;}#directLinkBox{height:auto!important;}.resultsBar{padding-left:4px;}#mbBody .resultsBar{left:49px;position:absolute;}#editws #mbBody .resultsBar{left:inherit!important;position:inherit!important;top:inherit!important;}#editws #mbBody #selectAll{float:left;}#editws #mbBody #clearAll{float:left;}.search_autosuggest_over{background-color:#55B0EB!important;color:white;cursor:pointer;}.printheadline{color:#333;font:1.8em Arial,Helvetica,sans-serif;margin-bottom:2px;}.nomargin{margin:0!important;}.nopadding{padding:0!important;}.ea #contentWrapper{width:100%!important;}.ea #contentWrapper input,.ea #contentWrapper textarea{width:90%!important;}#trackHeads33 .alertsHeader{float:left;}#trackHeads33 table td{vertical-align:middle;}#trackHeads33 .alertsHeader #folderDDLabel{margin-right:5px;color:#333;font-size:1.2em;line-height:26px;}#trackHeads33 .alertsHeader .alertsList{margin-right:5px;}.searchOptions{float:right;display:inline-block;height:23px;}.searchOptions .editAlert,.searchOptions .changeAccess,.searchOptions .alertOptions{display:inline-block;line-height:26px;padding:0 3px;color:#333;}.searchOptions .alertOptions{color:#55B0EB;}.searchOptions .alertOptions a{display:inline-block;background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat right -417px;padding:0 20px 0 0;}.alertOptions{position:relative;}.alertOptionsMenu{display:none;}.open .alertOptionsMenu{display:block;height:175px;width:200px;position:absolute;top:23px;right:0;background-color:#fff;border:1px solid #ccc;}.xmlLinkWithIcon{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat -340px -3px;}.xmlLinkWithIcon:hover{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat -340px -29px;}.alertList{display:inline-block;height:20px;position:relative;margin:0 5px 0 0;z-index:100;}.alertListLink{display:inline-block;width:212px;color:#333;line-height:20px;background:#eee url(../img/facelift/facelift-icon-sprite.gif) no-repeat right -498px;padding:0 5px;}.open .alertListLink,.alertListLink:hover{background-color:#d7d7d7;}.alertListMenu{display:none;position:absolute;width:200px;background-color:#fff;border:1px solid #ccc;}.open .alertListMenu{display:block;left:0;top:20px;}.alertListMenu ul li{padding:0;}.alertListMenu ul li .alertTypeSectionHead{display:block;line-height:12px;padding:3px 5px;background-color:#f3f3f3;}.alertListMenu ul li a{display:block;color:#333;line-height:12px;padding:2px 5px 2px 25px;vertical-align:top;}.alertListMenu ul li a:hover{background-color:#dbeefc;}* html .alertListMenu ul li .alertTypeSectionHead,* html .alertListMenu ul li a{height:12px;}.hr{height:100px;}#emtRow td{height:1px;}.ceprogress,.confirmDialog,.messageDialog{background-color:#fff;border:1px solid #ccc;font-family:Arial,Helvetica,sans-serif;font-size:11px;font-weight:bold;color:#000;-webkit-border-radius:3px;-moz-border-radius:3px;position:absolute;text-align:center;padding:10px 30px 10px 30px;}.confirmDialog,.messageDialog{border:5px solid #555;padding:20px 30px 15px 30px;}.ceerror{color:#f00;}#messageDialogOk td{padding-top:15px;text-align:center;}#messageDialogOk td ul{width:50px;float:none!important;}#messageDialogOk .btn{margin-left:0;}#confirmDialogButtons td{padding-top:15px;text-align:center;}#confirmDialogButtons td ul{width:120px;float:none!important;}#confirmDialogButtons #confirmDialogYes{margin-left:0;}.modalPage{margin:0;}.modalPage #contentWrapper{padding:0;width:800px;}#bottomSaveCanc{padding-right:48px;}.foldersDeliveryOptions table{padding:10px;width:100%;}.foldersDeliveryOptions td{padding:5px;}.foldersDeliveryOptions .delMnu{height:552px;width:100%;}.foldersDeliveryOptions .botButtonWrap .buttons{width:100%;}.foldersDeliveryOptions #tdFirst{width:33%;}.foldersDeliveryOptions #tdSecond{width:20%;}.foldersDeliveryOptions #tdThird{width:39%;}.foldersDeliveryOptions .itemText{margin-top:0;}#topBox{background-color:#fff;}#bottomBox{background-color:#fff;}.foldersDeliveryOptions .buttons li{padding:10px;}.foldersDeliveryOptions .buttons .btn{float:none;}.foldersDeliveryOptions .modalCancel{bottom:0;cursor:pointer;left:0;opacity:0;position:absolute;right:0;top:0;}#trOne{border-left:1px solid #999;padding-left:0;padding-right:0;background:none repeat scroll 0 0 #EEE;}#trTwo{border-left:1px solid #999;padding-left:0;padding-right:0;background:none repeat scroll 0 0 #EEE;}#tdOne{border-left:1px solid #999;padding-left:0;padding-bottom:0;padding-right:0;border-bottom:1px solid #999;border-right:1px solid #999;}#tdZeroRightP{padding-right:0;border-right:1px solid #999;border-top:1px solid #999;}#tdZeroRightPEX{border-top:1px solid #999;}*#tdZeroRightPEX{*border-left:1pxsolid#999;}#tdZeroRightPNoT{padding-right:10px;border-right:1px solid #999;border-bottom:1px solid #999;}#tdZeroRightPNos{border-bottom:1px solid #999;}*#tdZeroRightPNos{*border-left:1pxsolid#999;}.menuSelected{background-color:#dbeefb!important;}.menuItemC{color:#000;margin-top:2px!important;float:left;text-decoration:none;margin-left:4px;}.foldersDeliveryOptions .mnuItm{padding-top:2px;padding-bottom:2px;margin-top:2px;float:left;text-decoration:none;margin-left:4px;background-color:transparent;border-color:#999;border-width:1px;z-index:800;}.delMnu li,.delMSel li,.delASel li{z-index:900;}.delMnu li a,.delMSel li a,.delASel li a{z-index:800;}#afternoonListC select{border:none;}#morningListC select{border:none;}.foldersDeliveryOptions .delMnu ul{margin:0 0 2px;z-index:1;}.folderClosed{cursor:pointer;z-index:800;height:20px;}.delMSel a:focus,.delMSel a:hover,.delASel a:focus,.delASel a:hover,.delMnu a:focus,.delMnu a:hover{color:#000;}.delMSel{overflow:auto;height:200px;}.delASel{overflow:auto;height:200px;}#morningListC{margin-top:-3px;}#afternoonListC{margin-top:-3px;}.dragSelected{background-color:#dbeefb;}.deliveryOptions{margin-bottom:20px;}.botButtonWrap{margin-left:0;}.foldersDeliveryOptions .buttons .btn .prettyBtn span{color:#FFF!important;cursor:pointer;text-align:center;}.foldersDeliveryOptions .orderUp{cursor:pointer;background : url('../img/up.png?42.27.0')  no-repeat;height:24px;width:24px;margin-bottom:5px;}.foldersDeliveryOptions .orderDown{cursor:pointer;background : url('../img/down.png?42.27.0')  no-repeat;height:24px;width:24px;}*.foldersDeliveryOptions .buttons .btn .prettyBtn span{*width:115px;*margin-right:0;}#dcSaveAuxCntr .buttons .btn .prettyBtn span{color:#FFF!important;cursor:pointer;text-align:center;}.modalPage .modalFooter .buttons{padding-left:0;float:left;}.modalPage #dcSaveEditCntrL1{float:left;width:196px;}.modalPage #dcSaveEditCntrL2{float:left;}.modalPage #dcSaveCreateCntrL1{float:left;margin-top:20px;width:196px;clear:both;}.modalPage #dcSaveCreateCntrL2{float:left;margin-left:-3px;margin-top:20px;width:250px;}.modalPage #dcSaveCreateCntrL3{float:left;margin-left:-3px;width:250px;margin-top:20px;}.modalPageTopContainer{width:700px;}.modalPage #dcSaveBodyCntr{float:left;position:relative;padding-bottom:20px;width:810px;}.modalPage #RnmLnk{margin-left:5px;margin-right:5px;}.modalPage #dcSaveAuxCntr{float:left;margin-bottom:20px;position:relative;width:100%;}.modalPage #dcSaveAuxCntr td{width:300px;padding-left:20px;padding-right:20px;padding-top:2px;padding-bottom:2px;}#dcSaveAuxCntr .mnuItm{padding-top:3px;padding-bottom:2px;}#dcSaveAuxCntr .mnuItmSelected{padding-top:2px;padding-bottom:2px;background-color:#dbeefb;border-top:1px solid #BABCD1;color:black;}.SSeleted,.CSeleted{padding-top:2px;padding-bottom:2px;background-color:#dbeefb;border-top:1px solid #BABCD1;color:black;}#dcSaveAuxCntr .buttons li{margin-top:30px;float:none;}#dcSaveAuxCntr .botButtonWrap{width:124px;}#dcSaveAuxCntr .botButtonWrap .buttons{width:115px;float:none;}.mnuItmAdded{border:1px solid #BABCD1;background-color:#dbeefb!important;}#leftSControl,#rightSControl{padding-top:2px;padding-bottom:2px;margin-top:2px;background-color:transparent;height:400px;border:1px solid #BABCD1;width:265px;}#leftSControl .mnuItm,#rightSControl .mnuItm{background-color:transparent;margin-left:4px;}#leftSControl .folderClosed,#rightSControl .folderClosed{padding:2px;}#leftSControl .menuItemC,#rightSControl .menuItemC{margin-top:0!important;}#ContainerEAT p.button-row{text-align:left;}#ContainerEAT td{padding:3px;}#ContainerEAT .buttons .minorButton{opacity:0;bottom:0;cursor:pointer;left:0;position:absolute;right:0;top:0;}#ContainerEAT .botButtonWrap{float:none;clear:both;}#ContainerEAT .botButtonWrap .buttons{float:none;clear:both;}#ContainerEAT{clear:both;margin-bottom:-10px;}#sendDivE{margin-left:-10px;}#ContainerEAT .buttons .majorButton{opacity:0;bottom:0;cursor:pointer;left:0;position:absolute;right:0;top:0;}#emailSentC{width:520px;}#emailSentC ul{float:right;}#messageTop{margin-top:20px;margin-bottom:40px;}.lTD{text-align:right!important;width:170px;}#idNoResults{margin-bottom:40px;margin-top:20px;}#widgetFolderContainer div.tip{margin:10px 0 10px 5px;}.margin_10px{margin:10px;}.marginTop_10px{margin-top:10px;}.marginBottom_10px{margin-bottom:10px;}.marginRight_10px{margin-right:10px;}.marginTop_5px{margin-top:5px;}.marginBottom_5px{margin-bottom:5px;}.padding_10px{padding:10px;}.paddingBottom_15px{padding-bottom:15px;}.paddingBottom_10px{padding-bottom:10px;}.paddingBottom_0px{padding-bottom:0!important;}.paddingTop_10px{padding-top:10px;}.paddingRight_10px{padding-right:10px;}.paddingLeft_10px{padding-left:10px;}.paddingLeft_0px{padding-left:0!important;}.paddingLeft_5px{padding-left:5px;}.paddingRight_5px{padding-right:5px;}.txtBold{font-weight:bold;}.txtLight{color:#aaa;}.txtRight{text-align:right;}#articleViewAs ul li a.selected{background-color:#FFFFE3;}.overlaybody .close{display:none;}.articleParagraph b{font-weight:bold!important;}.odeArticle Table{padding:5px;}.odeArticle td{padding:5px;}.odeArticle p{margin-bottom:10px;}#SaveButCreate{margin-top:5px;margin-bottom:-10px;}#articleViewAs .pnlTab{width:100px;}#articleViewAs .pnlTabOpen{width:115px;}.cssQuotePage #contentLeft{float:left;}.cssQuotePage #inpfid{float:left;width:170px;}body.cssQuotePage #contentLeft,body.cssQuotePage #contentLeft div.module{width:320px;}.cssQuotePage #contentRight{margin-left:325px;height:100%;}.cssQuotePage b{font-size:100%;font-weight:bold;position:relative;top:-1px;}.cssQuotePage td,.cssQuotePage th{font-size:100%;}.cssQuotePage .title td{padding:5px;}#ml_main .buttons .btn .prettyBtn span{text-align:center;}.cssWidth2P{width:2%;background:none repeat scroll 0 0 #E8E8E8;}.cssWidth38P{width:38%;}.cssWidth60P{width:60%;}.css_ml_cellTD1{width:40%;}.css_ml_cellTD2{width:30%;}.css_ml_cellTD3{width:30%;}.ml_css_section{padding-bottom:10px;}#ml_sc_table1,#ml_sc_table2{width:100%;}#ml_co_table1,#ml_co_table2{width:100%;}#ml_qo_table1,#ml_qo_table2{width:100%;}#ml_sc_table2,#ml_co_table2,#ml_qo_table2{background-color:#FFF;border:1px solid #EFEFEF;}#ml_sc_table2 td,#ml_co_table2 td,#ml_qo_table2 td{border-bottom:1px solid #EFEFEF;font-size:10px;font-weight:normal;height:30px;padding:0;text-align:left;vertical-align:middle;}.css_ml_titlerow{padding:5px;background:#e8e8e8;}.css_ml_title{cursor:pointer;font-weight:bold;}.css_ml_header{padding:10px;background:#f5f5f5;font-weight:bold;}.css_ml_toggle{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -40px;height:18px;width:15px;cursor:pointer;}.css_ml_toggle.close{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -20px;}.css_ml_message{text-align:center;}.css_ml_cell{padding:8px;border-bottom:solid 1px #f5f5f5;border-left:solid 1px #f5f5f5;}.css_ml_row_hover{background:#CDE7FC;}.css_ml_cell_last{border-right:solid 1px #f5f5f5;}.css_ml_link{padding-left:10px;color:#55b0eb;cursor:pointer;}.css_ml_link:hover{padding-left:10px;color:#55b0eb;}.css_ml_separator{padding-left:10px;color:#ccc;}.overlaylist{height:90px;overflow:auto;border:solid 1px silver;overflow:auto;margin-bottom:5px;padding:5px;}.overlaybar{margin-bottom:5px;}.overlaysearchbutton{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -80px;width:20px;height:20px;margin-left:5px;cursor:pointer;}.appliedFilters:after,.DJIIFilterList:after,.connectionAndPillWrap:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.appliedFilters,.DJIIFilterList,.connectionAndPillWrap,.clearFix{zoom:1;}* html .appliedFilters,* html .DJIIFilterList,* html .connectionAndPillWrap,* html .clearFix{height:1%;}.DJIIFilterList li{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-bottom:3px;}.connectionAndPillWrap .filterConnection,.connectionAndPillWrap .filterPillWrap,.connectionAndPillWrap .filterType{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-right:5px;}#ml_co_searchnameonly{margin-right:10px;}.lf{cursor:pointer;}.spacer_10px{height:10px;overflow:hidden;}.dj_tophat-firstview{background : url('../img/tile_background.png?42.27.0')  repeat-x scroll 0 0 transparent;font-family:arial,sans-serif;position:relative;}.dj_tophat-firstview .dj_header-panel .wrap{margin:0 auto;padding-left:40px;padding-right:40px;}.dj_tophat-firstview .dj_information .wrap{background:none;height:194px;margin:0 auto;width:1025px;}.dj_tophat-firstview .dj_header-panel{background:none repeat scroll 0 0 #424242;border-bottom:1px solid #535353;height:30px;}.dj_tophat-firstview .dj_header-panel h1{color:white;float:left;font-size:12px;margin:8px 0 0;padding:0;cursor:pointer;font-weight:bold;}.dj_tophat-firstview .dj_header-panel h2.disable{background : url('../img/close_button.png?42.27.0')  no-repeat scroll right center transparent;color:#999;cursor:pointer;float:right;font-size:12px;margin-top:8px;padding:0 30px 0 0;}.dj_tophat-firstview .dj_information{background : url('../img/grid_background.png?42.27.0')  no-repeat scroll center center transparent;display:block;height:196px;}.dj_tophat-firstview .dj_information img{float:left;margin-top:10px;}.dj_tophat-firstview .dj_information h3.dj_beta{background : url('../img/beta_tag.png?42.27.0')  no-repeat scroll right top transparent;color:white;display:inline;font-size:26px;font-weight:normal;margin:0;padding:0 40px 0 0;text-shadow:0 0 5px #000;}.dj_tophat-firstview .dj_information .dj_text{float:right;margin-top:25px;width:630px;}.dj_tophat-firstview .dj_information p{color:white;font-size:16px;line-height:1.5;margin:10px 0 0;padding:0;width:400px;}.dj_tophat-firstview .dj_information ul.dj_next{float:right;margin-right:20px;}.dj_tophat-firstview .dj_information ul.dj_next li{display:inline;list-style-type:none;margin-right:20px;}.dj_tophat-firstview .dj_information ul.dj_next li a{color:white;font-size:12px;font-weight:bold;text-decoration:none;}.dj_tophat-firstview .dj_information ul.dj_next li.get_started a{-moz-border-radius:10px 10px 10px 10px;-webkit-border-radius:10px 10px 10px 10px;border-radius:10px 10px 10px 10px;background:none repeat scroll 0 0 #93BE4E;padding:5px 10px;}.dj_tophat-firstview .dj_information ul.dj_next li.later a{color:#CCC;}.cellPadding_3px td{padding:3px;}.cellPadding_5px td{padding:5px;}.cellValignTop td{vertical-align:top;}.cssArticleO .DJIIFilterList .pill .filterText{background-position:right -594px;}.cssArticleO .DJIIFilterList .pill:hover,.DJIIFilterList .active .pill{background-position:0 -402px;}.displayBlock{display:block;}.groupAdmin table.searchoptions td.Off{border:1px solid #fff!important;padding:1px!important;}#ml_sc_edit1overlay{height:470px;width:600px;}.admnSSID #ssidTable{background-color:#b1babb;}.pnlMnu li ul{margin:0 0 0 20px;padding:0;}.pnlMnu li{margin:0;padding:2px 0;}.pnlMnu ul{list-style-type:none;margin:0;padding:0 0 5px;}#dateAndDupRow .sbSubmit .floatRight{padding-right:10px;}#npModal .npMnu,#npModal .npMnu2{padding:0;}#npModal .npMnu ul{margin:0;}#npModal .mnuItm{margin-left:5px;}#npModal .mnuItm{background-color:transparent;}#npModal .mnuItmSelected{background-color:#DBEEFB!important;border:1px solid #BABCD1!important;}.addRemBtn .buttons .btn{float:none;margin-top:10px;}#npModal #issmd{margin-left:25px;}#npModal #ifmd{margin-left:25px;}#npModal #isosmd{margin-left:25px;}#npModal .svCBtn{float:right;width:200px;}#npModal .npMnu li{padding-top:2px;padding-bottom:2px;}#npModal .npMnu li ul{margin-left:17px;}#npModal .folderClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -134px -94px;margin-left:5px;}.sharedClosed{height:20px;}#npModal .sharedClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -104px -110px;margin-left:5px;}#npModal .buttons .btn .primaryBtnLeft span{text-align:center;}.norecords div{padding-left:25px;}#siteAlertMain .close a{background: transparent url('../img/close_icon.gif?42.27.0')  no-repeat 0 0;height:17px;position:absolute;right:18px;top:5px;width:17px;}.overlaycontainer #d1cnt span{display:inline-block;position:static;}.mnuBtnOff span{display:inline-block;position:relative!important;top:-5px!important;}#ml_sc_list .mnuBtnOff span{display:inline-block!important;position:static!important;}#ml_sc_list .mnuBtnOff{display:inline-block!important;position:static!important;}.overlaylist li ul li{margin-left:10px;}#ml_sc_editoverlay .searchBuilderFilters{position:relative;}#ml_sc_editoverlay .overlaylist{position:relative;}.btnWidth{width:130px!important;float:left;margin-bottom:10px;}.cqscTopDiv{margin:5px;padding-top:20px;}.cqscCodingS{float:left;width:110px;}.cqscSearchText{float:left;margin-left:10px;}.cqscBtnSear{float:left;width:100px;}.cqscSelectFromList{float:left;margin-top:10px;width:100px;}.cqscCompanyListControl{float:left;margin-right:10px;margin-top:10px;width:180px;}.cqscSelectList{float:left;width:110px;margin-top:10px;}.bdbulkmn{width:auto!important;}.tableCellPadding_5px td{padding:5px;}.tableCellPadding_3px td{padding:3px;}.tableCellPadding_5px th{padding:10px;}.actionNodes span{display:inline-block;}.quoteOuterD{height:340px;}.ssCOut{height:30px;}.ssC1but{width:100px;height:30px;}.ssC2but{height:30px;}#scl{width:180px;}#qicl{width:180px;}.mdsChartTitle{padding-top:10px;}.entrie table tbody tr th{padding-top:10px;padding-bottom:10px;font-weight:bold;}.entrie table tbody tr td{padding-top:5px;padding-bottom:5px;}#edittable td{padding:5px;align:center;}#edittable th{padding:5px;}#addtable td{padding-top:5px;padding-bottom:5px;}#addtable th{padding:5px;}.margin5PX{padding:5px;}.greyTbl th{padding:10px;}.width200PX{width:200px;}.width150PX{width:150px;}.width100PX{width:100px;}#ttDiv .btnTTC{margin-top:10px;}.cssPaddingRight10px{padding-right:10px;}.tt_mnuItmSelected{background-color:#DBEEFB!important;border:1px solid #BABCD1!important;}.pnlLst{vertical-align:top;height:22px;}.height80PX{height:115px!important;}.cssArticleO{height:182px;}#gl-navBottom{min-width:960px!important;}#gl-navBottomMiddle{min-width:960px!important;}* html .cssIE6MinWidth{*padding-left:1100px!important;*height:1px!important;}* html .cssIE6MinWidthAdj{*margin-left:-1100px!important;*position:relative!important;*height:1px!important;}* html .cssIE6MinWidthAdjLay{*height:1px!important;}.sbinfoIcon{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -304px transparent;display:inline-block;width:20px;}.addFIICodeIcon{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -144px transparent;display:inline-block;width:20px;}.searchoptions td a{color:#906;padding:2px 2px 2px 5px;}.searchoptions .searchContainer td{color:#000;font-weight:bold;border:0 solid white;}.searchoptions td{padding:3px;background-color:#EAEBF5;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-decoration:none;height:13px;border:1px solid white;}.searchoptions tr{color:#000;}.searchoptions #Header td{padding:3px;background-color:#999!important;color:#fff;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-decoration:none;font-weight:bold;height:13px;border:1px solid white;}.searchoptions #Header tr{color:#000;}#NoBody td{padding:2px;background-color:white;color:white;}div.content,div.exContent,div.contentWithTabs,div.scrContent{zoom:1;}.searchContainer{background : url('../img/bar_lt_news.gif?42.27.0')  no-repeat scroll;color:#000;font-family:Arial,Helvetica,sans-serif;text-decoration:none;margin-bottom:10px;padding-right:10px;position:relative;vertical-align:middle;zoom:1;}.searchContainer td{padding:3px;color:#000;border:none;}#npModal .subTitle{color:#FFF;}.overlaylist{position:relative;}.overlaylist #d1cnt{overflow:hidden;}.arHeadline{direction:rtl;unicode-bidi:embed;}.arsnippet{direction:rtl;unicode-bidi:embed;}.arTextAlign{text-align:left;}.sssuggest{padding-top:5px;margin:10px 0 0 37px;font:arial 12px;color:#666;border-top:#e6e7e8 1px solid;}#ssp{display:none;}#sspDiv{_width:560px;}.sspDesc{padding:0 0 10px 0;width:470px;margin:0 40px 0 40px;}.sspDesc1{text-align:center;padding:15px 0 20px 0;font-size:18px;font-weight:bold;}.sspDesc2{font-size:12px;}.sspDesc2 ul{list-style-type:none;padding:0;margin:0;}.sspDesc2 li{padding-bottom:10px;}.sspInputWrapper{border:1px solid #8c92b1;padding:10px 10px 10px 10px;margin-left:40px;margin-right:40px;white-space:nowrap;background-color:#e2e6f3;}.ssatx{font-size:16px;border:1px solid #d6d6d6;}.sspNoThanksDiv{padding:15px 0 15px 0;text-align:right;margin-left:20px;margin-right:20px;}#sspDiv div.floatRight{display:none;}#sspDiv,#sspDiv .popupHdr{background-color:#E1E1E1;}#sspBody{background-color:#EFEFEF;}.dj_emg_autosuggest_odd{background-color:#EEEDED!important;}.dj_emg_autosuggest_even{background-color:#FFF!important;}.dj_emg_autosuggest_over{background-color:#d8e2e5!important;color:Black!important;}.dj_emg_autosuggest_results{background-color:#FFF;z-index:100000!important;width:600px!important;}.scResultPopup{width:600px!important;}a.ac_info{background-image : url('../img/sbInfo.gif?42.27.0') !important;}a.ac_promote{background-image : url('../img/sbUpArrow.gif?42.27.0') !important;display:block!important;}.clsScrFrm a.ac_promote{background-image : url('../img/sbUpArrow.gif?42.27.0') !important;display:none!important;}#bkScrn{position:absolute;left:0;top:0;background:#A5A5A5;display:none;z-index:998;}a.ac_not{background: transparent url('../img/exclude.png?42.27.0')  no-repeat scroll center center!important;}* html #gl-navTop #gl-navTopLeft h1{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat 0 -209px;}* html #gl-navTopRightUl li#mbrightddtbm1,* html #gl-navTopRightUl li#mbrightddtbm0{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat right -4px;}* html #gl-navTopRightUl li#myDJFmenu{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat left -64px;}* html #gl-navTopRightUl li .settingsToolsDrop div .sectionTitle{background-image : url('../img/facelift/facelift-icon-sprite-darkgrayMatte.gif?42.27.0') ;}* html #gl-navBottom{background: transparent url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x 0 0;}* html #gl-navBottomMiddle{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -132px;}* html #gl-navBottomMiddle ul#menulist{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 -99px;}* html #gl-navBottomMiddle ul li.selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 0;}* html #gl-navBottomMiddle ul li.selected a{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -66px;}* html #gl-navBottomMiddle ul li.first-selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 -33px;}* html .footerBrand{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat scroll 0 -40px;}* html .ftright{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat scroll 0 -80px;}* html .fcsclose,* html .fcsopen{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}* html .pnlTab .pnlTabArrow{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -20px;}* html .pnlTabOpen .pnlTabArrow{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -40px;}* html .lkpBar .lkpBtn{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -80px;}* html .cd_title{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -659px transparent;}* html .sbTable .shadowTopLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px 0;}* html .sbTable .shadowTopRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -12px;}* html .sbTable .shadowLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  repeat-y 0 0;}* html .sbTable .shadowRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  repeat-y -12px 0;}* html .sbTable .shadowBotLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -36px;}* html .sbTable .shadowBotRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -24px;}* html .menulist li a{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat 0 0;}* html .tblNav .tblToggleBtn{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -40px transparent;}* html .tblNav .tblToggleBtn.tblToggleBtnPlus{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -20px transparent;}* html .firstDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -322px transparent;}* html .secondDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -342px transparent;}* html .scheduledDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -382px transparent;}* html .continuousDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -363px transparent;}* html .onlineDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -683px transparent;}* html .xmlLink.xmlLinkWithIcon{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -400px transparent;}* html .DJIIFilterList .pill,* html .DJIIFilterList .pill .filterText,* html .DJIIFilterList .pillNoMenu,* html .DJIIFilterList .pillNoMenu .filterText,* html .DJIIFilterList .filterConnection,* html .DJIIFilterList .filterConnection .connectionText,* html .pillOptionsList .pillOption,* html .pillOptionsList .pillOption span{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html #fdtHldContainer{background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;}* html .cd_expand{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}* html .buttons .btn .prettyBtn{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html .buttons .btn .prettyBtn span{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html .nextItem,* html .previousItem{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}#qooverlay .buttons{margin-top:16px;}#qooverlay .overlayline{margin-bottom:5px;}#qocompanylist{height:70px;overflow:auto;position:relative;}.overlaycompanylistProgress{border:1px solid #CCC;}.NewsPages #contentWrapper #contentLeft{float:left;width:36%;}.NewsPages #contentWrapper #contentRight{float:left;margin-left:15px;width:59%;}.cssRemoveOverFlowIPAD{height:auto!important;overflow:hidden!important;}.NewsLetter{margin:0;}.WorkSpace{margin:0;}.NewsLetter #contentWrapper{padding:0;}.cssGroupFolder{background : url('../img/blueDott.JPG?42.27.0')  no-repeat scroll 0 0 transparent!important;height:10px;padding-left:15px;}.cssNoDisplay{display:none;}.snippet b{font-weight:bold;}.pagePadding{margin-left:10px;margin-right:10px;}#NLContainer td{padding:0;}#mbBody #selectAll,#mbBody #selectAll a{height:17px;width:15px;}#mbBody #selectAll,#mbBody #selectAll a{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -245px -130px transparent;}#mbBody #clearAll,#mbBody #clearAll a{height:17px;width:15px;}#mbBody #clearAll,#mbBody #clearAll a{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -245px -150px transparent;}#mbBody .headlineHeader{padding-bottom:5px;background-color:#ccc;padding-left:5px;padding-right:5px;padding-top:5px;margin-bottom:10px;height:1%;}.showButllet{background : url('../img/arrowb.gif?42.27.0')  no-repeat 2px 4px transparent!important;zoom:1;}.overlaylist .lookupdyn{display:none;}a.sbIcon img{display:inline-block!important;vertical-align:baseline!important;}.overlaycontainer .mnuItmInc{color:#55B0EB!important;text-decoration:none!important;}.overlaycontainer .mnuItmExc{color:#55B0EB!important;text-decoration:line-through!important;}.overlaycontainer .addFiiCode{display:none!important;}.overlaycontainer a.sbIcon{width:0!important;padding-left:5px;}.overlaycontainer .availLbl{margin-left:25px;_margin-left:15px;}.overlaycontainer .availLbl img{_margin-bottom:5px;}#mdsLookupControl a:visited,#mdsLookupControl a:link,#mdsLookupControl a:hover{text-decoration:underline!important;}#chrtHCorpBond .WidgetContainer{background-color:#e5e5e5!important;}.WidgetBodyControls{position:relative;}.overlaylist .availSrchLbl{margin-left:25px!important;}.overlaylist .sbImg{margin-left:10px!important;}.NewsFiltersFilter{-moz-border-radius:5px;display:block;float:left;line-height:20px;margin-right:5px;padding-left:5px;margin-bottom:2px;background-position:0 -402px;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;}.NewsFiltersFilter .label{float:left;line-height:20px;white-space:nowrap;}.NewsFiltersFilter .icon-close{background-image : url('../img/icon_filter_close.png?42.27.0') ;background-position:center top;cursor:pointer;display:block;float:left;height:20px;width:20px;}.NewsFiltersFilter .icon-close:hover{background-position:center bottom;}.filterTextRemove{background-position:right -857px!important;}.DJIIFilterList .pill:hover .filterTextRemove,.DJIIFilterList .active .pill .filterTextRemove{background-position:right -892px!important;}.alphaHdr{background-color:#F0F0F0!important;cursor:default;}.alphaHdr a{padding-right:3px;}#dialogWindow .header .close{background-image:none!important;}body.framed #headlines{overflow:auto;overflow-x:hidden;}body.framed #headlineFrame{float:left;width:50%;}#returnToHeadlines{display:none;}body.articleView #returnToHeadlines{display:inline-block;margin:4px 0 0;vertical-align:middle;position:relative;}#returnToHeadlines a{padding:4px;}body.articleView #ppsview,body.articleView #viewSelected,body.articleView #headlineSort,body.articleView #dedupDropdown{display:none;}#headlineSort,#viewSelected{display:inline;}#pageFooter{clear:both;}.headline a:active{color:#007ec5;text-decoration:none;}.headline a:hover{color:#007ec5;text-decoration:underline;}.headline a:visited,.headline a:visited{color:#007ec5;text-decoration:none;}.headline a.moreLikeThis,.headline a.moreLikeThis:visited{color:blue;font-weight:normal;text-decoration:none;}#headlines a b,.headlines a b{color:#000;}.headline a.moreLikeThis:hover{color:blue;font-weight:normal;text-decoration:underline;}.searchPreview td{border-bottom:solid 1px #CCC;padding:3px 0 3px 8px;}.searchPreview .label{color:#666;}body.framed #bottomHeadlineNav,body.articleView #bottomHeadlineNav{display:none;}body.headlinesView #bottomHeadlineNav{display:block;}div.indexingHeader span.left,div.indexingHeader span.right{float:left;position:relative;}div.indexingHeader span.right{float:right;}#articleFrame a.moreLikeThis{color:#666;text-decoration:none;}#articleFrame a.moreLikeThis:hover{color:#000;text-decoration:underline;}.indexingHeader{background-color:#FC3;font-weight:bold;padding:7px;}.indexingPanel{background-color:#FF9;}.articleComment{background-color:#FFC;padding:3px;}a.carryOverRmv:hover{color:Red;font-size:14px;font-weight:600;line-height:13px;text-decoration:underline;}.folderList{width:175px;}.viewType{padding-top:5px;}body.articleView .viewType{display:none;}span.hot{border:solid 1px #CCC;}span.hot span{border-left:solid 10px #F00;color:#F00;}span.new{border:solid 1px #CCC;}span.new span{border-left:solid 10px #F69;color:#F69;}span.mustRead{border:solid 1px #CCC;}span.mustRead span{border-left:solid 10px #9C0;color:#9C0;}span.comment{border:solid 1px #CCC;}span.comment span{border-left:solid 10px #FC0;color:#FC0;}#newsstandTitle{float:left;padding-bottom:10px;}#returnLink{float:right;padding-bottom:10px;}span.hldScore{font-weight:bold;}.linkhide{float:right;margin-right:10px;cursor:pointer;padding-right:1px;}div.dymFreeText{padding-bottom:0;margin-bottom:0;margin-right:10px;display:inline-block;height:20px;vertical-align:middle;width:100%;}* html div.dymFreeText{height:20px;padding-top:4px;padding-bottom:0;margin-bottom:0;margin-right:10px;}div.recognitiondym,#appliedFilters{padding-top:5px!important;padding-bottom:0!important;margin-top:2px;}div.recognitiondym{background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x scroll 0 0 transparent;margin:5px 0;padding-left:5px;border:solid 1px #DBDBE7;display:block;}.freeText{padding-left:5px;}.dymTitle{display:block;}.dymInput{padding:1px;margin:0;}.dymCollapsiblePanel{padding-top:3px;}.dymCollapsiblePanelCollapsed{padding-top:3px;display:none;}.dedupHd{display:none;}#dedupHoverHint{background-color:#FFFFC6;border:1px solid #CCC;font-size:10px;padding:5px;position:absolute;visibility:hidden;width:285px;z-index:10000;}#dedupHiddenHH{display:none;}dedupHoverHintShim{position:absolute;}.dedupCount{color:#309;font-style:normal;}#analyzeChecked{background-color:#F63;background-repeat:repeat-x;color:#FFF;font-family:Arial,Helvetica,sans-serif;font-size:11px;height:16px;padding-bottom:1px;padding-left:4px;padding-right:4px;padding-top:1px;text-align:center;}#analyzeChecked A:active,#analyzeChecked A:visited,#analyzeChecked A:link,#analyzeChecked A:hover{color:#FFF;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-align:center;text-decoration:none;}.hintImg{border:0;padding:0;vertical-align:middle;}#feedHH{display:none;}.hoverHint{background-color:#FFFFC6;border:1px solid #CCC;font-size:10px;padding:5px;position:absolute;visibility:hidden;z-index:10000;}body.articleView TABLE#contentColumns{table-layout:fixed;}.viewAs{display:none;}body.articleView #articleViewAs{display:inline-block;}body.articleView #returnToPreviousPage{display:inline-block;margin:4px 0 0;vertical-align:middle;position:relative;}body.articleView #returnToPreviousPage a{display:block;padding:4px;}.hlAuthorLink{font-weight:normal;}.headline .leadFields a{color:#63c;font:1em Verdana,Geneva,sans-serif;font-weight:normal;text-decoration:none;}.headline .leadFields a:hover{color:#63C;font-weight:normal;text-decoration:underline;}#atlnk{outline:none;}.headerTd{background:#ffd659;padding:2px;}div.tabcontent{background:#FFFFE3;}#navtab table tr #tabselected,#navtab table tr #tabselected td{background:#FFFFE3;}#navtab table tr td table{cursor:pointer;}#ssButtonContainer{background : url('../img/left_button.gif?42.27.0')  no-repeat left center;height:32px;padding-left:5px;cursor:pointer;display:inline-block;_width:1%;}#ssButtonSubContainer{background : url('../img/right_button.gif?42.27.0')  no-repeat right center;height:32px;padding-right:5px;display:inline-block;}#ssButtonContent{background : url('../img/bg_button.gif?42.27.0')  repeat-x center center;height:32px;text-align:left;padding-left:5px;padding-right:5px;display:inline-block;font-size:10px;}#ssButtonContent2{padding-top:2px;font-weight:bold;white-space:nowrap;}#ssButtonContent3{font-weight:bold;color:#76D6FF;white-space:nowrap;}.ssButtonContent4{font-weight:bold;color:#FD0606;white-space:nowrap;height:32px;text-align:center;vertical-align:middle;padding-top:8px;}#likeThese{display:none;}#likeTheseDiv{width:450px;}.likeTheseHeader{font-weight:bold;}.likeTheseInputWrapper{padding:10px 5px 5px 5px;margin-left:10px;}.likeTheseSaveNoThanksDiv{padding:10px 20px 20px 10px;text-align:right;}#likeTheseDiv div.floatRight{display:none;}#likeTheseDiv .popupHdr{background : url('../img/nlPopupTabBG.gif?42.27.0')  repeat-x scroll right bottom transparent;}#likeTheseBody{background-color:#FFF;}.arHeadline{margin-left:5px;direction:rtl;unicode-bidi:embed;}.arsnippet{direction:rtl;unicode-bidi:embed;}.arTextAlign{text-align:left;}.arArticle{text-align:right;}.ararticleParagraph{direction:rtl;unicode-bidi:embed;text-align:right;}.arLeadField{text-align:right;}.arArticle table{width:100%;}#headlineTabs.selectedTabAll #articleViewAs{display:none;}a, a:hover,.headline a,.headline a:hover,.headline a:active,.headline a:visited {text-decoration:none;color:#000;cursor:text;}#contentWrapper {border:none;background:none;}img,input, select,#menubarleft,#menubarright,#navcontainer ul,#breadtrail,#postProcessingNav,.content-header a,.industryReportHeader a {visibility:hidden;display:none;}#navcontainer {margin:40px 10px 0 10px;padding:0px 10px 0 10px;border-bottom:solid 1px #DEDEE9;}#navcontainer h1 {margin:0;padding:0;font-size:24px;font-weight:normal;}#navcontainer .djrlogo {visibility:visible;}#snapshotHeader {border:none;}#headlineFrame, #carryOver {padding-left:10px;}.article {page-break-after:always;}#lastArticle {page-break-after:auto;}html>body #lastArticle {page-break-after:avoid;}</style>

</head>
<body class=''><div id="navcontainer" class="fcpNavContainer">
<table cellpadding="0" cellspacing="0" border="0" width="100%">
<tr>
<td class="factivalogo"><h1>Factiva</h1></td>
<td class="djrlogo" align="right"><span>Dow Jones</span></td>
</tr>
</table>
</div>
<form name="PageBaseForm" method="post" action="/aa/default.aspx?pp=Save&amp;hc=Publication" id="PageBaseForm">
<div>
<input type="hidden" name="_XFORMSESSSTATE" id="_XFORMSESSSTATE" value="AB57MDp7MTU5Ons4OiJtYm0wLTAiLDA6MCwyOiJTIiwzOlsiMTQ2Il0sNDoiZW4iLDWABQJ1YWxidLwEDTE6MSwyOjAsMzoiMkNBTiJgBQZhbm5hLm1haEB8BARlcnRhLmNhaAcPIjE2Iiw2OnswOns0OiIwMDg2bAgNImNvZXhlLDAsMDtjb3RyboQBAA1lbnR3c2pwLDI7Y29jdXMsMCIsMToiZHRtb24sMCJ9cAEAFjgyMjIwNEY2ODAwMkE0MDA3MjEyNDY0MkJERDY4NUUwMjQwRTgwMHxqAHwwMQQAAy0xIn0sN5gRBzEyOiJBbGwiLDGdATFcCwsyNiwyOjF9LDg6MCwxMIUce3gAwR59jBADRjA4QzIwfAwPODAyNjAwMUJDfDAyMTAwMTEwKQMAMjEydQEzcAAFMDAxMDAzMDKgEgYifX0sNjowLDe0LwAHIn0sVToiL2FhL2RlZmF1bHQuYXNweCJ9fREAAKcBAAA=" />
<input type="hidden" name="_XFORMSTATE" id="_XFORMSTATE" value="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" />
<input type="hidden" name="__VIEWSTATE" id="
__VIEWSTATE" value="" />
</div>
<div id="contentWrapper"><div id="contentLeft"><span></span><div  class="article enArticle"><p>
<div>Business news (ibnews)</div>
<div id="hd" ><b class='enHeadline'>Gene therapy trial approved</b>
</div><div class="author">Maggie Hartford   </div><div>329 words</div><div>10 November 2010</div><div>The Oxford Times</div><div>NQTNC</div><div>English</div><div>© Copyright 2010 Newsquest Digital Media   </div>
</p>
<p class="articleParagraph enarticleParagraph">GENE therapy company <span class="companylink">Oxford Biomedica</span> has received approval from US regulators to test its eye disease treatment on 18 patients.</p>
<p class="articleParagraph enarticleParagraph">The company, based at Oxford Science Park, uses an equine virus to deliver genes to the retina in the hope of repairing damage from age-related macular degeneration, a major cause of blindness.</p>
<p class="articleParagraph enarticleParagraph">The treatment, called RetinoStat, was designed using the company's patented LentiVector gene-delivery technology, and is one of four treatments being developed in partnership with pharmaceutical giant <span class="companylink">Sanofi-aventis</span>.</p>
<p class="articleParagraph enarticleParagraph">The trial at the Wilmer Eye Institute at Johns Hopkins, Baltimore, led by Prof Peter Campochiaro, will evaluate three dose levels and assess safety, aspects of visual acuity and ocular physiology. It is hoped to start by the end of December.</p>
<p class="articleParagraph enarticleParagraph">Age-related macular degeneration is a major cause of blindness affecting an estimated 25 to 30 million people worldwide and is expected to triple by 2025.</p>
<p class="articleParagraph enarticleParagraph">RetinoStat aims to preserve and improve the vision of patients through blocking the formation of new blood vessels. Lab tests suggests patients will only need a single dose, while current treatments often require frequent, repeated administration.</p>
<p class="articleParagraph enarticleParagraph">Chief executive John Dawson said: “This is a significant milestone for <span class="companylink">Oxford BioMedica</span> and is a result of the outstanding effort from our research and development and regulatory teams."</p>
<p class="articleParagraph enarticleParagraph">It is the first US clinical study to directly administer this type of treatment to patients, and he said the approval boosted hopes for the company's Parkinson’s disease product, ProSavin.</p>
<p class="articleParagraph enarticleParagraph">He added: "Together with our partner, <span class="companylink">Sanofi-aventis</span>, we look forward to progressing all four of our gene-based ocular products into clinical development by the end of 2011.”</p>
<p class="articleParagraph enarticleParagraph">The loss-making company, an Oxford University spin-out, had £13.7m cash at the end of September, compared with £16.3m in June. Its hopes are pinned on meeting development milestones triggering payments from its commercial partners over the next 12-18 months.</p>
<p>Document NQTNC00020101110e6ba000b7</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>Help Charlie hear before he is blind</b>
</div><div class="author">By Ben Falconer Chief Reporter ben.falconer@glosmedia.co.uk   </div><div>582 words</div><div>30 October 2010</div><div>The Citizen</div><div>CITIZN</div><div>1</div><div>19</div><div>English</div><div>© 2010 The Citizen   </div>
</p>
<p class="articleParagraph enarticleParagraph">EMMA and Matthew Denton's life is a marriage made in music.</p>
<p class="articleParagraph enarticleParagraph">Half of an award-winning string quartet, the couple, from St Cyrills Road, Stonehouse, play and teach across the globe and back home in Gloucestershire.</p>
<p class="articleParagraph enarticleParagraph">But a chance matching of genes means their son Charlie, four, has Usher's Syndrome which severely affects his hearing and one day could blind him.</p>
<p class="articleParagraph enarticleParagraph">"We knew we were well matched but not so well matched that we share the same gene," said cellist Emma, who, with violinist Matt, 33, and Eoin and Michelle Schmidt-Martin, form the Carducci Quartet.</p>
<p class="articleParagraph enarticleParagraph">Charlie was diagnosed with Type 1B Usher's, the most severe, in June and now there's a race against time to make sure he can hear and speak as clearly as possible before he loses his sight.</p>
<p class="articleParagraph enarticleParagraph">Key to that is Auditory Verbal therapy, which costs £9,000 for two years.</p>
<p class="articleParagraph enarticleParagraph">"He was tested for hearing at two days old and he passed on his right ear and nearly passed on his left," said Emma. "At age one, they said 'what colour hearing aids do you want?' I had no idea."</p>
<p class="articleParagraph enarticleParagraph">Agonising When she asked a doctor how much he could hear, she was told Charlie would only just pick up an aeroplane taking off right next to him.</p>
<p class="articleParagraph enarticleParagraph">Diagnosis came an agonising 11 months later after tests.</p>
<p class="articleParagraph enarticleParagraph">Now Charlie could start losing his sight from the age of 10. His parents hope gene therapy and eye microchips currently being researched in the USA, could be developed by the time Charlie reaches his teens.</p>
<p class="articleParagraph enarticleParagraph">They opted for cochlear implants, which are "amazing" said Emma, 33.</p>
<p class="articleParagraph enarticleParagraph">"He is now hearing down to 30 decibels, which is the same as whispering in a quiet room."</p>
<p class="articleParagraph enarticleParagraph">To get the best from the implants, he needs the therapy.</p>
<p class="articleParagraph enarticleParagraph">"It's to get him to listen, rather than just speak and he could get age-appropriate speech within a couple of years," said Emma. "As well as developing speech patterns, it is key for him to learn to listen. "It's crucial to get him hearing before the eye sight deteriorates."</p>
<p class="articleParagraph enarticleParagraph">They recently ran the Nottingham Marathon and Half Marathon to raise sponsorship, and, with the help of Stroud District Lions Club, organised a Carducci Quartet concert at St Laurence Church, Stroud in August.</p>
<p class="articleParagraph enarticleParagraph">Well over £3,600 was raised from both events.</p>
<p class="articleParagraph enarticleParagraph">The Woodchester-based Gyde Charity, which assists children who are blind, deaf or partially blind, has made a donation.</p>
<p class="articleParagraph enarticleParagraph">He has a sister, Daisy, two, to contend with, who along with Charlie attends Wycliffe nursery in Stonehouse.</p>
<p class="articleParagraph enarticleParagraph">There is a 25 per cent chance she has Usher's.</p>
<p class="articleParagraph enarticleParagraph">What is Usher's Syndrome? and the disorder can range in terms of its effectiveness.</p>
<p class="articleParagraph enarticleParagraph">Usher's Syndrome is a rare genetic disorder that causes deafness and blindness. It is characterised by deafness and gradual vision loss, which usually takes hold in the first decade of a person's life. The first symptoms to appear are night blindness and a slow narrowing of vision, Figures of the number of people with it in the UK are incomplete, but in the USA about three in every 100,000 people are diagnosed with it.</p>
<p class="articleParagraph enarticleParagraph">Find out more at www.carducciquartet.co.uk[http://www.carducciquartet.co.uk].</p>
<p>THERAPY HOPE: Four-year-old Charlie Denton. Below: Charlie with dad Matt, mum Emma and sister Daisy, two.    </p>
<p>Document CITIZN0020101101e6au0002x</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>FOUND, THE GENE THAT CAUSES SHORT-SIGHT</b>
</div><div class="author">BY FIONA MACRAE SCIENCE REPORTER   </div><div>860 words</div><div>13 September 2010</div><div>Daily Mail</div><div>DAIM</div><div>06</div><div>English</div><div>(c) 2010 Associated Newspapers. All rights reserved   </div>
</p>
<p class="articleParagraph enarticleParagraph">NOW EXPERTS SAY CONDITION COULD BE HALTED BY EYE DROPS</p>
<p class="articleParagraph enarticleParagraph">A GENE that causes shortsightedness has been pinpointed by British scientists, paving the way for eye drops that could make glasses history.</p>
<p class="articleParagraph enarticleParagraph">Within just ten years, a drug that prevents short- sightedness or stops it in its tracks could be in widespread use.</p>
<p class="articleParagraph enarticleParagraph">Millions would be spared the inconvenience and expense of contact lenses, spectacles and laser surgery.</p>
<p class="articleParagraph enarticleParagraph">Given in childhood, the eye drops could also spare school pupils anxieties about having to wear glasses.</p>
<p class="articleParagraph enarticleParagraph">Short- sightedness, or trouble in focussing on distant objects, affects</p>
<p class="articleParagraph enarticleParagraph">more than one in three Britons and is becoming more common as we spend more time indoors and in front of computer screens.</p>
<p class="articleParagraph enarticleParagraph">Caused by overgrowth of the eyeball, it usually starts developing in childhood. In some cases vision can rapidly deteriorate. There is no way of halting its progress and, in severe cases, it leads to blindness.</p>
<p class="articleParagraph enarticleParagraph">The latest research, by an international team led by experts at King s College London and published in the prestigious journal Nature Genetics, offers hope to millions.</p>
<p class="articleParagraph enarticleParagraph">To find the gene, the first to be linked to short-sightedness, or myopia, the researchers compared the DNA of more than 4,000 British twins. Twins are often used in such studies because it is easier distinguish the different effects of nature and nurture.</p>
<p class="articleParagraph enarticleParagraph">They then confirmed their results by studying the genetics of another 13,000 British, Dutch and Australian individuals.</p>
<p class="articleParagraph enarticleParagraph">Some 45 per cent of Britons have the rogue gene and those who have two copies of it are almost twice as likely to be short-sighted as those who are free of it. KCL researcher Dr Pirro Hysi, the study s lead author, said: We have known for many years that the most important risk factor for being short-sighted is having parents who are shortsighted and for the first time we are identifying genes that may be involved in passing on this susceptibility.</p>
<p class="articleParagraph enarticleParagraph">The gene, known as RASGRF1, is thought to play a key role in the development of the eye and the passing of visual signals to the brain for processing. When it is faulty, the eyeball may over-grow, making distant objects seem fuzzy or blurred.</p>
<p class="articleParagraph enarticleParagraph">Dr Chris Hammond, also of KCL, said: Myopia, or shortsightedness, is the most common eye problem, affecting over a third of adults in the UK.</p>
<p class="articleParagraph enarticleParagraph">People who are extremely short-sighted carry significant risks of future vision loss. The retina can peel away from the back of the eye like wallpaper off a wall.</p>
<p class="articleParagraph enarticleParagraph">While we believe that environ-mental risk factors such as a lot of close work and lack of outdoor activity are implicated, we have not previously understood how people become short-sighted.</p>
<p class="articleParagraph enarticleParagraph">We hope that by understanding the mechanisms we can stop children from becoming shortsighted and stop short-sighted children from becoming more short-sighted.</p>
<p class="articleParagraph enarticleParagraph">A second study, by Dutch researchers, identified a second short- sightedness gene. Ultimately, there could be dozens behind the condition.</p>
<p class="articleParagraph enarticleParagraph">Drugs that counter their effect and stop the eyeball from over-growing could be available in just a decade, said Dr Hammond. Other options include gene therapy injecting healthy genes into the eye.</p>
<p class="articleParagraph enarticleParagraph">But Dr Hammond said: Gene therapy is a major intervention. I think we are going to be looking at developing some kind of eye drop or tablet that interferes with the biological pathway that leads to short-sightedness. Although the eye drops would not help adults who are already short-sighted, they could be of huge benefit to their children.</p>
<p class="articleParagraph enarticleParagraph">However, today s youngsters can take some simple steps to try to discourage short-sighted-ness. Terri Young, of Duke University in North Carolina in the U.S., said: People need to go out-side and look at the horizon.</p>
<p class="articleParagraph enarticleParagraph">Today s near work forces our eyes to be constantly in tension to focus on reading papers and watching monitors.</p>
<p class="articleParagraph enarticleParagraph">Professor Pete Coffey, director of the London Project to Cure Blindness, cautioned that any drug would have to be shown to be extremely safe before it was given to children.</p>
<p class="articleParagraph enarticleParagraph">f.macrae@dailymail.co.uk</p>
<p class="articleParagraph enarticleParagraph">LEGACY OF POOR VISION</p>
<p class="articleParagraph enarticleParagraph">˜ Genes are largely to blame for short-sightedness. If one of your parents is short-sighted, there is a one in three chance you will be. ˜ If both your parents are short-sighted, there is a one in two chance you will be too. ˜ Environmental factors such as close work and lack of sunlight also play a role, explaining why the condition is becoming more common in urban and computerised societies. ˜ The main symptom of myopia is distant objects appearing blurred, while near objects are seen clearly. Other symptoms can include headaches and tired eyes. ˜ In those who are shortsighted, light rays are focused in front of the retina s receptor cells (the inside of the back of the eye), rather than right on it. This is because the eye is over-enlarged and too long from front to back, or the cornea (the front of the eye) is too curved.</p>
<p>Document DAIM000020100912e69d00017</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Gene therapy cures congenital form of blindness.</b>
</div><div>153 words</div><div>26 October 2009</div><div>The Independent</div><div>THEIN</div><div>English</div><div>(c) 2009 Elsevier Engineering Information   www.ei.org[http://www.ei.org]</div>
</p>
<p class="articleParagraph enarticleParagraph">Exhilarated scientists announced on 24 Oct 2009 that they had used gene therapy to restore eyesight to children blighted by a rare, inherited form of creeping blindness. The revolutionary treatment targets a disease of light-catching retinal cells called Leber's congenital amaurosis, or LCA. Caused by flaws in any one of around 13 key genes, LCA triggers severe loss of vision and abnormal eye movements in early infancy, usually leading to total blindness in the twenties or thirties. Doctors led by Jean Bennett of the University of Pennsylvania School of Medicine, USA tested a way of tackling this tragedy by inserting a corrective gene in a disabled cold virus. Their study was published online by The Lancet on 24 Oct 2009, coinciding with a presentation at a conference of American ophthalmologists in San Francisco.</p>
<p class="articleParagraph enarticleParagraph">The Independent</p>
<p class="articleParagraph enarticleParagraph">Website: http://www.independent.co.uk[http://www.independent.co.uk]</p>
<p>Document THEIN00020091030e5aq00003</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Colour blindness</b>
</div><div>97 words</div><div>21 September 2009</div><div>The Evening Chronicle, Newcastle</div><div>EVECHR</div><div>3</div><div>English</div><div>(c) 2009 The Newcastle Chronicle & Journal Ltd   </div>
</p>
<p class="articleParagraph enarticleParagraph">SCIENTISTS have cured colour blindness in monkeys, bringing hope to millions of human sufferers worldwide.</p>
<p class="articleParagraph enarticleParagraph">Researchers from the University of Washington and the University of Florida made the breakthrough with two squirrel monkeys using gene therapy.</p>
<p class="articleParagraph enarticleParagraph">Experts believe the news casts a rosy light on the potential to treat adult vision disorders involving "cone cells" - the most important human vision cells. Ophthalmic molecular geneticist, Prof William Hauswirth, said: "Although colour blindness is only moderately lifealtering, we've shown we can cure a cone disease in a primate, and that it can be done very safely."</p>
<p>Document EVECHR0020090921e59l00008</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Cure for colour blindness</b>
</div><div>367 words</div><div>19 September 2009</div><div>Daily Post (North Wales)</div><div>DPO</div><div>8</div><div>English</div><div>(c) The Liverpool Daily Post & Echo Ltd, 2009.  </div>
</p>
<p class="articleParagraph enarticleParagraph">SCIENTISTS have cured colour blindness in monkeys, bringing hope to millions of human sufferers worldwide.</p>
<p class="articleParagraph enarticleParagraph">Researchers from Washington and Florida universities made the breakthrough with two squirrel monkeys using gene therapy.</p>
<p class="articleParagraph enarticleParagraph">Experts believe it has potential to treat adult vision disorders involving cone cells - the most important human vision cells.</p>
<p class="articleParagraph enarticleParagraph">Ophthalmic molecular geneticist Professor William Hauswirth said: "Although colour blindness is only moderately life-altering, we've shown we can safely cure a cone disease in a primate.</p>
<p class="articleParagraph enarticleParagraph">"That's extremely encouraging for the development of therapies for human cone diseases that really are blinding."</p>
<p class="articleParagraph enarticleParagraph">The finding is also likely to intrigue millions of people around the world who are colour blind - including about 3.5 million people in the United States, more than 13 million in India and more than 16 million in China.</p>
<p class="articleParagraph enarticleParagraph">The problem mostly hits men, leaving about 8% of white American men incapable of discerning red and green hues - important for everyday things like recognising traffic lights.</p>
<p class="articleParagraph enarticleParagraph">"People who are colour blind feel that they are missing out," said Jay Neitz, a professor of ophthalmology at the University of Washington.</p>
<p class="articleParagraph enarticleParagraph">"If we could find a way to do this with complete safety in human eyes, as we did with monkeys, I think there would be a lot of people who would want it.</p>
<p class="articleParagraph enarticleParagraph">"Beyond that, we hope this technology will be useful in correcting lots of different vision disorders."</p>
<p class="articleParagraph enarticleParagraph">Neitz and his wife Maureen trained two squirrel monkeys named Dalton and Sam to tell which colours they saw, using a standard vision-testing technique called the Cambridge Colour Test.</p>
<p class="articleParagraph enarticleParagraph">The tests are similar to ones given to children the world over, in which students are asked to identify a pattern of coloured dots. The researchers devised a computer touch screen the monkeys could use to trace the colour patterns. When the animals chose correctly, they received a reward of grape juice.</p>
<p class="articleParagraph enarticleParagraph">Gerald Jacobs, a professor of psychology at the University of California, who was not involved in the research, said: "There are still questions about safety, but in these monkeys at least, there were no untoward effects."</p>
<p class="articleParagraph enarticleParagraph">. Call NHS Wales Direct on 0845 46 47 with health concerns</p>
<p>Document DPO0000020090919e59j00015</p></div><br/><span></span><div  class="article enArticle"><p>
<div>Guardian Home Pages</div>
<div id="hd" ><b class='enHeadline'>National: Colour blindness breakthrough</b>
</div><div class="author">Ian Sample, Science correspondent </div><div>243 words</div><div>17 September 2009</div><div>The Guardian</div><div>GRDN</div><div>10</div><div>English</div><div>© Copyright 2009.  The Guardian.  All rights reserved. </div>
</p>
<p class="articleParagraph enarticleParagraph">Two squirrel monkeys that were colour-blind from birth have had their vision restored after receiving gene therapy.</p>
<p class="articleParagraph enarticleParagraph">The experiment paves the way for the treatment of a range of genetic eye disorders in humans, including some that cause full or partial blindness in millions of people worldwide.</p>
<p class="articleParagraph enarticleParagraph">Sam and Dalton, two male squirrel monkeys, were able to see the world in full colour five months after being treated, doctors said. The animals were born without an ability to see the colour red.</p>
<p class="articleParagraph enarticleParagraph">The therapy targets specialised "cone" cells in the eye which allow animals - including humans - to see in colour.</p>
<p class="articleParagraph enarticleParagraph">Genetic damage to cone cells, which causes colour blindness, is the most common type of gene disorder seen in humans. The condition mostly affects men, around 5% of whom are unable to distinguish between red and green hues.</p>
<p class="articleParagraph enarticleParagraph">"Although colour blindness is only moderately life-altering, we've shown we can cure a cone disease in a primate, and that it can be done very safely," said William Hauswirth at the University of Florida. "That's extremely encouraging for the development of therapies for human cone [diseases] that are really blinding."</p>
<p class="articleParagraph enarticleParagraph">Researchers treated the monkeys by injecting them with a virus that had been modified to carry a corrective gene.</p>
<p class="articleParagraph enarticleParagraph">The researchers have begun clinical trials to test the gene therapy as a treatment for a rare form of childhood blindness.</p>
<p>Document GRDN000020090917e59h0002w</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>Hope is in sight</b>
</div><div>79 words</div><div>17 September 2009</div><div>Daily Star</div><div>DAISTA</div><div>4</div><div>English</div><div>(c) copyright Express Newspapers 2009  </div>
</p>
<p class="articleParagraph enarticleParagraph">SCIENTISTS using gene therapy have cured colour blindness in monkeys in a world first that offers hope to millions.</p>
<p class="articleParagraph enarticleParagraph">It could not only allow colour-blind people to tell red from green - it may restore sight to the blind.</p>
<p class="articleParagraph enarticleParagraph">Researcher Jay Neitz, of the University of Washington in Seattle, said: "If we could fi nd a way to do this with complete safety in human eyes, we could correct a lot of vision disorders."</p>
<p>Document DAISTA0020090917e59h0000m</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>New hope of cure for the colour blind</b>
</div><div class="author">By Victoria Fletcher Health Editor    </div><div>450 words</div><div>17 September 2009</div><div>The Daily Express</div><div>THEEXP</div><div>8</div><div>English</div><div>(c) 2009 Express Newspapers    </div>
</p>
<p class="articleParagraph enarticleParagraph">A NEW discovery by genetic scientists could bring a cure for colour blindness and other diseases that can lead to a total loss of sight.</p>
<p class="articleParagraph enarticleParagraph">Researchers in the US made the breakthrough after successfully using gene therapy to treat a pair of squirrel monkeys that could not differentiate between red and green.</p>
<p class="articleParagraph enarticleParagraph">It could bring new treatments for a variety of different diseases that are triggered by faulty cone cells at the back of the eye.</p>
<p class="articleParagraph enarticleParagraph">The problem affects millions of people in this country and can lead to diseases such as macular degeneration, which often causes complete blindness.</p>
<p class="articleParagraph enarticleParagraph">Men are most commonly affected by colour blindness. About 8 per cent find it difficult to differentiate between, for example, red and green.</p>
<p class="articleParagraph enarticleParagraph">The research, led by Jay Neitz, professor of ophthalmology at the University of Washington, has been published in the scientific journal Nature.</p>
<p class="articleParagraph enarticleParagraph">Professor Neitz said: "People who are colour blind often feel that they are missing out. If we could find a way to do this with complete safety in human eyes, as we did with monkeys, I think there would be a lot of people who would want it.</p>
<p class="articleParagraph enarticleParagraph">"Beyond that, we hope this technology will be useful in correcting lots of different vision disorders."</p>
<p class="articleParagraph enarticleParagraph">Professor Neitz and wife Maureen, also a professor of ophthalmology, began training the two squirrel monkeys - whom they named Dalton and Sam - to recognise colour more than 10 years ago.</p>
<p class="articleParagraph enarticleParagraph">For the new research, the animals' colour receptor cone cells were injected with a pigment gene but it wasn't until weeks later that they began to differentiate between red and green.</p>
<p class="articleParagraph enarticleParagraph">Scientists also devised a technique called the Cambridge Colour Test, which enabled the monkeys to tell them what colours they were seeing.</p>
<p class="articleParagraph enarticleParagraph">The tests are similar to ones that are given to children. Subjects are asked to identify a specific pattern of dots placed among a field of others that vary in size, colour and intensity.</p>
<p class="articleParagraph enarticleParagraph">The team of researchers in Washington came up with a computer touch-screen that the monkeys could use to trace the colour patterns. When the animals chose correctly, they were given a reward.</p>
<p class="articleParagraph enarticleParagraph">Ophthalmic molecular geneticist, Professor William Hauswirth, of the University of Florida, believes the developments were extremely encouraging and offered the hope of a safe treatment for cone cell conditions.</p>
<p class="articleParagraph enarticleParagraph">He said: "Although colour blindness is only moderately life-altering, we've shown that we can cure a cone disease in a primate, and that it can be done very safely.</p>
<p class="articleParagraph enarticleParagraph">"That's extremely encouraging for the development of therapies for human cone diseases that really are blinding."</p>
<p>Document THEEXP0020090917e59h0000p</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>Fresh hope for the colour-blind as gene cure makes monkeys see red - and green</b>
</div><div class="author">Hannah Devlin   </div><div>765 words</div><div>17 September 2009</div><div>The Times</div><div>T</div><div>1</div><div>31</div><div>English</div><div>(c) 2009 Times Newspapers Limited. All rights reserved   </div>
</p>
<p class="articleParagraph enarticleParagraph">Genetic scientists have discovered a cure for colour blindness, offering hope to millions of sufferers.</p>
<p class="articleParagraph enarticleParagraph">Scientists at the University of Washington, in Seattle, and the University of Florida restored normal vision to two colour-blind monkeys. The technique could prove to be a safe and effective cure for colour blindness and other visual disorders related to the cones in the retina.</p>
<p class="articleParagraph enarticleParagraph">"Although colour blindness is only moderately life-altering, we have shown we can cure a cone disease in a primate and that it can be done very safely," said Professor William Hauswirth, an ophthalmic molecular geneticist at the University of Florida. "That is extremely encouraging for the development of therapies for human cone diseases that really are blinding."</p>
<p class="articleParagraph enarticleParagraph">Those suffering from red-green colour blindness cannot distinguish between colours in the green-red-yellow part of the spectrum. This can make reading maps, using the internet and selecting a matching shirt and tie impossible. The disorder affects about 8 per cent of Caucasian males, but fewer than 0.5 per cent of females. Normal colour vision requires three types of cone in the retina, sensitive to light in the blue, green, and red parts of the spectrum. The squirrel monkeys in the study - Dalton and Sam - lacked a gene called L opsin that codes for the red-sensitive cone. The same gene defect causes most cases of redgreen colour blindness in humans.</p>
<p class="articleParagraph enarticleParagraph">In the study, published today in the journal Nature, scientists restored normal vision to the monkeys by injecting a virus modified to contain the L opsin gene into the retina. Over 24 weeks the light sensitivity of the cones infected with the virus shifted towards the red part of the spectrum. In a touchscreen test the monkeys were able to discriminate easily between patterns of grey, green and red dots.</p>
<p class="articleParagraph enarticleParagraph">The success of the treatment in adult animals demonstrated that the brain is able to rewire itself to take advantage of new receptors. It had been expected that the treatment of congenital vision disorders would be effective only if administered at a young age.</p>
<p class="articleParagraph enarticleParagraph">The virus used to deliver the L optin gene, called adeno-associated virus, is not known to cause disease in humans and has already been approved for use in human gene therapy trials for cystic fibrosis, haemophilia and Parkinson's disease. Two years on from the colour blindness study, the monkeys have shown no adverse effects from the treatment.</p>
<p class="articleParagraph enarticleParagraph">Scientists are now looking to obtain permission to begin trials in colourblind humans. "People who are colour-blind feel that they are missing out," Jay Neitz, a professor of ophthalmology at the University of Washington, said. "If we could find a way to do this with complete safety in human eyes I think there would be a lot of people who would want it."</p>
<p class="articleParagraph enarticleParagraph">Celebrity sufferers Mark Twain writer, Peter Ebdon snooker player, Meat Loaf singer, Jack Nicklaus golfer, Bing Crosby singer, Bob Dole US politician, Bill Clinton US President, Keanu Reeves actor, Bill Beaumont England rugby captain, Chris Rogers Australian cricketer</p>
<p class="articleParagraph enarticleParagraph">X marks the spot in men</p>
<p class="articleParagraph enarticleParagraph">Analysis Hannah Devlin</p>
<p class="articleParagraph enarticleParagraph">About 8 per cent of Caucasian men but fewer than 0.5 per cent of women are colour-blind. The reason for this lies in a genetic Achilles' heel particular to males.</p>
<p class="articleParagraph enarticleParagraph">The genes that code for the red and green cones are adjacent to each other on the X chromosome and, unluckily for men, are prone to getting mixed up when being copied from one generation to the next.</p>
<p class="articleParagraph enarticleParagraph">This kind of copying mistake can result in an X chromosome that is missing either a red or a green cone gene, or one with two slightly different red cones or two slightly different green cones. For women, who have a pair of X chromosomes, this is not normally a problem: they have a back-up. Men, however, have only one chance at getting it right.</p>
<p class="articleParagraph enarticleParagraph">The blue cone gene is on an entirely different chromosome, which explains why blue colour blindness is vanishingly rare in both sexes. Everyone gets two copies of all the chromosomes outside X and Y, and so a mutation in the blue gene would have to occur twice within a generation.</p>
<p class="articleParagraph enarticleParagraph">Possessing a single X chromosome leaves men susceptible to a range of other so-called X-linked disorders including haemophilia and muscular dystrophy.</p>
<p>The monkeys identifying colours. In the test, right, colour-blind people see the figure 21; the normally sighted will see 74    </p>
<p>Document T000000020090917e59h0004x</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>Colour-blindness cured in monkeys</b>
</div><div>98 words</div><div>17 September 2009</div><div>Metro</div><div>METRO</div><div>1</div><div>9</div><div>English</div><div>(c) 2009 Associated Newspapers. All rights reserved.   </div>
</p>
<p class="articleParagraph enarticleParagraph">Colour-BlINd monkeys have been cured - bringing hope to millions of human sufferers. Gene therapy has cast light on the potential to treat adult vision disorders involving 'cone cells' - the most important human vision cells. uS researchers worked with the makers of a standard vision-testing technique to allow two squirrel monkeys to 'tell' them which colours they were seeing. 'Although colour-blindness is only moderately life-altering, we've shown we can cure a cone disease in a primate and that it can be done very safely,' said Prof William Hauswirth.</p>
<p>Document METRO00020090917e59h00082</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News:</div>
<div id="hd" ><b class='enHeadline'>Scientists offer hope to colour blind</b>
</div><div class="author">By Kate Devlin
Medical Correspondent    </div><div>165 words</div><div>17 September 2009</div><div>The Daily Telegraph</div><div>DT</div><div>014</div><div>English</div><div>(c) 2009 Telegraph Group Limited, London    </div>
</p>
<p class="articleParagraph enarticleParagraph">A CURE for colour blindness in monkeys could help millions of human sufferers and have implications for other inherited genetic eye defects.</p>
<p class="articleParagraph enarticleParagraph">Researchers proved that the brain can "rewire'' itself to see things it has never been able to see before. Colour blindness affects more than one million men and more than 100,000 women in Britain.</p>
<p class="articleParagraph enarticleParagraph">Scientists used gene therapy to cure the monkeys of colour blindness. A harmless virus that delivers corrective genes to the retina was injected into the eyes of two squirrel monkeys, who had been colour blind since birth.</p>
<p class="articleParagraph enarticleParagraph">Within weeks a protein produced by the corrective genes allowed both monkeys to make out reds and greens. The researchers, from the universities of Washington and Florida, called the results "startling''. Because human DNA was used in the injections, very little would have to be changed before clinical trials could begin, they said in the study published in Nature.</p>
<p>Document DT00000020090917e59h0003r</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>COLOUR BLINDNESS CURE; FIONA MACRAE</b>
</div><div>495 words</div><div>17 September 2009</div><div>Daily Mail</div><div>DAIM</div><div>21</div><div>English</div><div>(c) 2009 Associated Newspapers. All rights reserved   </div>
</p>
<p class="articleParagraph enarticleParagraph">SCIENTISTS have cured colour blindness in monkeys in a world first.</p>
<p class="articleParagraph enarticleParagraph">As well as allowing colourblind humans to tell red from green, the innovative technique could restore sight to the blind.</p>
<p class="articleParagraph enarticleParagraph">Sufferers of age-related macular degeneration - the most common cause of blindness in the elderly - are among the millions who could eventually benefit.</p>
<p class="articleParagraph enarticleParagraph">Researcher Jay Neitz said: 'If we could find a way to do this with complete safety in human eyes, as we did with monkeys, there would be a lot of people who would want it.</p>
<p class="articleParagraph enarticleParagraph">'We hope the technology will be useful in correcting a lot of different vision disorders.'</p>
<p class="articleParagraph enarticleParagraph">Professor Neitz used gene therapy - injections of genes - to allow two male squirrel monkeys called Sam and Dalton to see in full colour for the first time.</p>
<p class="articleParagraph enarticleParagraph">Like some humans with red-green colour blindness, the monkeys lacked a pigment that the cones - the colour-detector cells at the back of the eye - need to see red and green. As a result, they saw both red and green as shades of grey. Other colours, such as orange, blue and brown appeared washed-out.</p>
<p class="articleParagraph enarticleParagraph">To fix their vision, the U.S. scientists injected their eyes with millions of copies of a gene needed to make the missing pigment, the journal Nature reports.</p>
<p class="articleParagraph enarticleParagraph">Importantly, the monkeys were injected with a human gene, suggesting the same technique would work on people. Four months later, their vision suddenly improved. Professor Neitz, of the University of Washington in Seattle, said: 'It was as if they woke up and saw these new colours. They unquestionably responded to colours that had been invisible to them.'</p>
<p class="articleParagraph enarticleParagraph">A version of the colour blindness test that is used in schools around the world showed just how much their vision has improved.</p>
<p class="articleParagraph enarticleParagraph">Dr Katherine Mancuso, the study's lead author, said: 'Their performance on red and green was similar, but not quite as good, as a female monkey who had normal colour vision since birth.' But the need to prove that adding genes to the body does not cause harmful side-effects means it will be some time before the method is routinely used to correct colour blindness.</p>
<p class="articleParagraph enarticleParagraph">Despite this, the researchers are optimistic and point out that gene therapy is already being tested on Britons and Americans with a rare, hereditary form of blindness called Leber's congenital amaurosis.</p>
<p class="articleParagraph enarticleParagraph">The technique could also be adapted to treat other conditions that involve problems with genes in the colour and detail-detecting cone cells at the back of the eye. These include age-related macular degeneration, in which deterioration of central vision makes it increasingly difficult to carry out everyday tasks such as reading and driving. Blindness linked to diabetes might also be treated.</p>
<p class="articleParagraph enarticleParagraph">Cathy Yelf, of the Macular Disease Society, said the research was 'very interesting' but cautioned: 'A practical gene therapy for macular degeneration is still some way off.'</p>
<p class="articleParagraph enarticleParagraph">f.macrae@dailymail.co.uk</p>
<p>Document DAIM000020090916e59h0003o</p></div><br/><span></span><div  class="article enArticle"><p>
<div>Features</div>
<div id="hd" ><b class='enHeadline'>Ape aid for colour blind</b>
</div><div>74 words</div><div>17 September 2009</div><div>Mirror</div><div>DMIRR</div><div>30</div><div>English</div><div>(c) 2009 Mirror Group Ltd    </div>
</p>
<p class="articleParagraph enarticleParagraph">SIGHT</p>
<p class="articleParagraph enarticleParagraph">SCIENTISTS have cured colour blind monkeys, raising hopes they can do the same for people.</p>
<p class="articleParagraph enarticleParagraph">The US team in Seattle used gene therapy to make the eye more sensitive to red light. One in eight men are unable to differentiate between green and red.</p>
<p class="articleParagraph enarticleParagraph">Prof Jay Neitz said: "If we could find a way to do this in complete safety, a lot of people would want it."</p>
<p>Document DMIRR00020090917e59h0004s</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Blindness success</b>
</div><div>54 words</div><div>17 September 2009</div><div>The Journal, Newcastle</div><div>THEJOU</div><div>6</div><div>English</div><div>(c) 2009 The Newcastle Chronicle & Journal Ltd   </div>
</p>
<p class="articleParagraph enarticleParagraph">WORLD TODAY: HEALTH</p>
<p class="articleParagraph enarticleParagraph">SCIENTISTS have cured colour blindness in monkeys, bringing hope to millions of human sufferers worldwide. Researchers from two US universities made the breakthrough with two squirrel monkeys using gene therapy. Experts believe the news casts a rosy light on the potential to treat adult vision disorders involving "cone cells".</p>
<p>Document THEJOU0020090917e59h0000g</p></div><br/><span></span><div  class="article enArticle"><p>
<div>Compact Main Book - Features</div>
<div id="hd" ><b class='enHeadline'>It's been pointed out to me that in last week's column about people who suffer from the eye disease retinitis pigmentosa, or usher, I failed to mention that the disease is often associated with deafness and that usher usually starts in the early twenties and can be hereditary if both parents harbour the gene.</b>
</div><div>631 words</div><div>29 August 2009</div><div>Belfast Telegraph</div><div>WBEL</div><div>First</div><div>22</div><div>English</div><div>(c)2009 Independent News & Media (Northern Ireland). All Rights Reserved.    </div>
</p>
<p class="articleParagraph enarticleParagraph">Features</p>
<p class="articleParagraph enarticleParagraph">It's been pointed out to me that in last week's column about people who suffer from the eye disease retinitis pigmentosa, or usher, I failed to mention that the disease is often associated with deafness and that usher usually starts in the early twenties and can be hereditary if both parents harbour the gene.</p>
<p class="articleParagraph enarticleParagraph">The disease is incurable and one can only admire the spirit of those like Rebecca Atkinson who face up to it positively and write about it with hope and humour.</p>
<p class="articleParagraph enarticleParagraph">There has been no decline in the number of deaf babies being born in spite of the various inoculation programmes and it will be interesting to see how far parents will avail themselves of the speculative gene therapy remedies being proposed.</p>
<p class="articleParagraph enarticleParagraph">We all want our children to be perfect, but how far should we go in seeking medical or surgical help?</p>
<p class="articleParagraph enarticleParagraph">Some deaf parents of deaf children, on the other hand, see no problem at all and are perfectly happy to communicate by sign language and introduce their children to the deaf community they know and love.</p>
<p class="articleParagraph enarticleParagraph">But hearing parents see things very differently and I had an interesting chat with the father of three-year-old twins who had been born three months premature. We got talking about early-year education and I asked him what he would have done if they had been born deaf.</p>
<p class="articleParagraph enarticleParagraph">He admitted there was always the worry of things going wrong and he rejoices that the twins are now so healthy; but he was very specific that if the children had been deaf he would have gone for all the medical help available to aid communication -- including cochlear implants if they were considered appropriate.</p>
<p class="articleParagraph enarticleParagraph">Deafness, he said, interferes with the natural acquisition of language and all means of overcoming it are viable, including sign language if that is what the child requires.</p>
<p class="articleParagraph enarticleParagraph">Education for the majority now takes place in mainstream schools with help from digital aids and other modern aids to communication. This is excellent for those able to cope in this challenging environment, but care needs to be taken to ensure those children with more severe hearing loss don't miss out.</p>
<p class="articleParagraph enarticleParagraph">I've met hearing parents with deaf children now in their teens who regret bitterly not spending more time with them when small and making them more often aware of family matters even if it was only the tittle-tattle of daily life.</p>
<p class="articleParagraph enarticleParagraph">It's good for parents to remember that all legs of a three legged stool are important and that the teaching at school and the child's natural intelligence needs to be combined with daily and regular stimulation at home so that he or she is satisfied both intellectually and socially.</p>
<p class="articleParagraph enarticleParagraph">Deaf children cannot easily learn subconsciously the way hearing children do and parents can help enormously by keeping them entertained and aware.</p>
<p class="articleParagraph enarticleParagraph">My wife lost her hearing at five and is forever grateful to her mother for buying suitable books and encouraging her to read.</p>
<p class="articleParagraph enarticleParagraph">As I write this, the Irish deaf sports team are on their way to the Deaflympics in Seoul and my friend and IDSA president Larry Coogan admits that, with all the changes going on in education and the growing number of competitors with hearing aids and other technical aids, sign language users are in the minority and the definition of deafness is changing fast.</p>
<p>Document WBEL000020090829e58t0002w</p></div><br/><span></span><div  class="article enArticle"><p>
<div>Compact Main Book - Features</div>
<div id="hd" ><b class='enHeadline'>Several years ago I was asked to meet a couple of delegates flying to Belfast for a major conference on retinitis pigmentosa. They were strangers to me and I was given no information about them apart from their names, but I was assured there would be no difficulty recognising them as they should stand out from the crowd.</b>
</div><div>650 words</div><div>22 August 2009</div><div>Belfast Telegraph</div><div>WBEL</div><div>First</div><div>22</div><div>English</div><div>(c)2009 Independent News & Media (Northern Ireland). All Rights Reserved.    </div>
</p>
<p class="articleParagraph enarticleParagraph">Features</p>
<p class="articleParagraph enarticleParagraph">Several years ago I was asked to meet a couple of delegates flying to Belfast for a major conference on retinitis pigmentosa. They were strangers to me and I was given no information about them apart from their names, but I was assured there would be no difficulty recognising them as they should stand out from the crowd.</p>
<p class="articleParagraph enarticleParagraph">I got to the arrival hall at Belfast International in good time and eyed the passengers carefully, but of them there was no sign. Then I noticed a couple of women who seemed to be staring with unusual intensity at each other as they talked. It was them.</p>
<p class="articleParagraph enarticleParagraph">Retinitus pigmentosa, or usher, as it is more commonly known, causes the photoreceptive cells on the retina to die off triggering, in the majority of cases, tunnel vision. Central vision remains intact, but peripheral vision deteriorates to almost nothing.</p>
<p class="articleParagraph enarticleParagraph">I was invited to attend one of the seminars and, wearing special sight-limiting glasses took part in such simple exercises as throwing and catching a tennis ball. It was utterly impossible, humiliating and depressing for the five minutes or so I wore the restrictive glasses.</p>
<p class="articleParagraph enarticleParagraph">Rebecca Atkinson has been in such a position for the past 13 or 14 years and writes about it in her occasional column in The Guardian. "In the early years after my diagnosis, blindness remained an elusive and terrifying concept. Every year I would visit the doctor and he would say the same thing -- that I must live and plan my life with the certainty that blindness was inevitable. And so, slowly over time, that is what I learned to do.</p>
<p class="articleParagraph enarticleParagraph">"But now the advent of gene therapy has pushed open a chink in the door. Disabled people have long asked themselves the hypothetical 'would you be cured if you could?' question. Now, for the first time, there is a chance, albeit very small, that maybe one day I might actually get my sight back."</p>
<p class="articleParagraph enarticleParagraph">Rebecca goes on to say that instead of being thrilled she feels a bit confused. She can understand the arguments of those who say those born blind are pitied for having never seen a sunset or the look in their lover's eyes, but what, she asks, "if your soul is sighted, and then you go blind?".</p>
<p class="articleParagraph enarticleParagraph">I understand that argument very well as I've been told many times over the past 10 years or so that I should undergo a cochlear implant operation to restore at least part of my hearing. Now scientists are talking about gene therapy to prevent the birth of deaf babies ... and not just alleviate but even cure lifelong deafness. I've discussed this with my deaf friends and I have to report that they display an almost unanimous desire to remain as they are and to keep their deaf identity.</p>
<p class="articleParagraph enarticleParagraph">I've been deaf since the age of 11 and see things differently. Yes, I've enjoyed a very happy married life and made many good friends in the deaf community, but I remain convinced that God created us to function with five senses and deafness deprives us of many life-enhancing things you are unable to appreciate unless you've had it and then lost it.</p>
<p class="articleParagraph enarticleParagraph">I want to hear birdsong, I want to be able to go to concerts as the urge takes me, I want to be able to relax at home listening to the stirring music of my boyhood. Yes, I want to get back to the way I was.</p>
<p>Document WBEL000020090822e58m0000w</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News:</div>
<div id="hd" ><b class='enHeadline'>Gene injection offers hope to the blind</b>
</div><div class="author">By Kate Devlin
Medical Correspondent   </div><div>193 words</div><div>13 August 2009</div><div>The Daily Telegraph</div><div>DT</div><div>008</div><div>English</div><div>(c) 2009 Telegraph Group Limited, London   </div>
</p>
<p class="articleParagraph enarticleParagraph">A GROUNDBREAKING therapy to treat blindness by injecting healthy genes into the eye improved patients' sight a thousand fold a year after the initial treatment.</p>
<p class="articleParagraph enarticleParagraph">Researchers said that the therapy appeared to cause "stable'' improvement and triggered adaptations in the brain. The treatment was tested on three patients with a rare, incurable form of blindness called Leber's congenital amaurosis.</p>
<p class="articleParagraph enarticleParagraph">"These results are very significant because they represent one of the first steps toward the clinical use of gene therapy for an inherited form of blindness,'' said Dr Paul Sieving, the director of the National Eye Institute in Washington, which was involved in the trial.</p>
<p class="articleParagraph enarticleParagraph">"I anticipate that it is only a matter of time before similar techniques will be applied to other genetic diseases affecting vision.'' Although the treatment did not improve the patients' ability to read letters on an eye chart, all three can now detect very dim lights that they were previously unable to see.</p>
<p class="articleParagraph enarticleParagraph">The findings were reported online in the journal Human Gene Therapy and in a letter in The New England Journal of Medicine.</p>
<p>Document DT00000020090813e58d0001l</p></div><br/><span></span><div  class="article enArticle"><p>
<div>Daily Main Book - News</div>
<div id="hd" ><b class='enHeadline'>Patient, heal thyself</b>
</div><div class="author">Steve Connor and Jeremy Laurance   </div><div>1501 words</div><div>22 November 2008</div><div>The Independent</div><div>IND</div><div>1ST</div><div>English</div><div>(c) 2008 Independent & Media PLC   </div>
</p>
<p class="articleParagraph enarticleParagraph">News | The idea of growing your own new organ is now a reality. The possibilities are endless, say Steve Connor and Jeremy Laurance</p>
<p class="articleParagraph enarticleParagraph">Surgeons crossed another medical frontier this week with the transplant of a windpipe grown from stem cells - the "mother" cells of the body capable of developing into specialised tissue. The success of the operation in Barcelona on Claudia Castillo, a 30-year-old mother-of-two, proved what scientists have long promised - that stem cells can now be used to fashion replacement body parts.</p>
<p class="articleParagraph enarticleParagraph">The success of the medical procedure has opened the door to other possible breakthroughs in regenerative medicine - which is when damaged body parts are repaired in situ rather than being removed and replaced by whole organ transplants. Medical scientists believe that few body parts will be left untouched by the technical, genetic and surgical breakthroughs that could revolutionise medicine in the 21st century.</p>
<p class="articleParagraph enarticleParagraph">The Eye</p>
<p class="articleParagraph enarticleParagraph">British scientists claimed a world first last April after they helped a blind man to see with an injection into the back of the eye. Steven Howarth, 18, from Bolton, who had a rare inherited eye disorder which left him unable to see in low light, improved sufficiently after the treatment to be able to navigate a maze in conditions similar to street lighting at night.</p>
<p class="articleParagraph enarticleParagraph">He was one of the first three patients with eye disorders to be treated with gene therapy - an injection of normal versions of the defective gene that caused his condition, Leber's congenital amaurosis. Scientists at Moorfield hospital, London, said it would lead to other eye treatments.</p>
<p class="articleParagraph enarticleParagraph">The Windpipe</p>
<p class="articleParagraph enarticleParagraph">Claudia Castillo made history as the first patient to receive a whole organ transplant grown using her own stem cells and without the need for powerful anti-rejection drugs.</p>
<p class="articleParagraph enarticleParagraph">Surgeons used a windpipe from a donor which they stripped of all living cells and re-seeded with cells grown in the laboratory from Ms Castillo's bone marrow. The transplant was carried out last June and blood tests have shown no sign of rejection.</p>
<p class="articleParagraph enarticleParagraph">The Bladder</p>
<p class="articleParagraph enarticleParagraph">American specialists announced a breakthrough in 2006 by growing parts of new bladders in the laboratory from patients' own stem cells and successfully implanting them. Seven patients given the new bladders had functioning organs that performed as well as those conventionally repaired.</p>
<p class="articleParagraph enarticleParagraph">The breakthrough demonstrated the potential of regenerative medicine - growing your own tissues and organs.</p>
<p class="articleParagraph enarticleParagraph">Scientists at the Institute for Regenerative Medicine in North Carolina, where the operations were carried out, are working on 20 tissues and organs, including blood vessels and hearts.</p>
<p class="articleParagraph enarticleParagraph">The procedure involved taking cells from the patient's bladder, which was grown on a biodegradable "scaffold"After eight weeks, it was used to patch the damaged organ. The repaired bladder was working well up to seven years later, when the breakthrough was announced.</p>
<p class="articleParagraph enarticleParagraph">The Skin</p>
<p class="articleParagraph enarticleParagraph">Chronic wounds are already treated by grafting pieces of the patient's own skin, which is usually taken from the thigh, onto the affected area. However, this can result in unsightly scarring at two places on the body.</p>
<p class="articleParagraph enarticleParagraph">Another technique being developed is to grow skin - dermal tissue - in the laboratory using adult stem cells extracted from the roots of hairs plucked from the back of the scalp. Scientists can grow numerous small patches of skin using this technique. These skin patches can then be transplanted on to the wounded area to regrow the skin over the damaged tissue without scarring or the risk of tissue rejection, which occurs when donor skin is used.</p>
<p class="articleParagraph enarticleParagraph">Scientists at the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, have been given a licence to grow skin in this way from patients with conditions that result in open wounds, such as leg ulcers.</p>
<p class="articleParagraph enarticleParagraph">The Immune System</p>
<p class="articleParagraph enarticleParagraph">The body's defensive system against invading diseases can be regenerated or replaced in a number of ways. One of the most successful is by a transplant using donated umbilical cord blood for children with severe combined immune deficiency (Scid), when they lack the white blood cells of the immune cells produced by the bone marrow.</p>
<p class="articleParagraph enarticleParagraph">The transplanted stem cells repopulate the patient's bone marrow. An alternative is to create embryonic stem cells from a patient's own skin cells and convert them into the stem cells of the immune system, in which case there would be no need for immunosuppressant drugs.</p>
<p class="articleParagraph enarticleParagraph">The Brain & Nerves</p>
<p class="articleParagraph enarticleParagraph">In one technique, stem cells are extracted from cloned embryos created from a patient's skin cells and used to create mature nerve cells that can be transplanted into damaged areas of the brain. Another strategy is to block production of the protein inhibitors within nerve cells that are thought to prevent regeneration.</p>
<p class="articleParagraph enarticleParagraph">The Face</p>
<p class="articleParagraph enarticleParagraph">The world's first face transplant carried out by French surgeons on Isabel Dinoire in 2005 made headlines around the world. It marked a breakthrough because of the intricate surgery required to reconnect the scores of nerves and blood vessels which supply the face. She had been savaged by her dog after taking a cocktail of drugs in an apparent suicide attempt.</p>
<p class="articleParagraph enarticleParagraph">Mme Dinoire, 38, was given a new mouth, nose and chin and the success of the operation was judged in part on how effectively her new face regenerated to restore her sense of identity. Three years on, she admitted she had still not come to terms with her new face which was "not hers, it's somebody else's".</p>
<p class="articleParagraph enarticleParagraph">Doctors at the Royal Free Hospital, London, have been given ethical permission to carry out a further face transplant and hope to refine the technique.</p>
<p class="articleParagraph enarticleParagraph">The Heart</p>
<p class="articleParagraph enarticleParagraph">French doctors unveiled the latest version of the mechanical heart last month, which is claimed to beat almost exactly like the real thing. Made of titanium and animal tissue, the device uses electronic sensors to regulate the heart rate and blood flow and is even said to fool cardiologists when they are shown its ECG trace.</p>
<p class="articleParagraph enarticleParagraph">Existing artificial hearts are designed as a stop-gap, to help people over transplant operations or while they are waiting for a new organ. In some cases they are used to "rest" the patient's own heart, to give it time to recover from infection or disease until it is ready to take over its function as the body's main pump circulating the blood.</p>
<p class="articleParagraph enarticleParagraph">British patients have been implanted with artificial hearts for up to two years, before having them removed and allowing their own hearts to pump again.</p>
<p class="articleParagraph enarticleParagraph">The Pancreas</p>
<p class="articleParagraph enarticleParagraph">Doctors have been seeking a treatment for diabetes for decades that avoids the need for daily injections of insulin. Since 2000, a dozen patients have received transplanted islet cells, the insulin-producing cells in the pancreas, from dead donors which have worked with varying degrees of success. The Department of Health agreed this year to fund further research, involving 80 patients annually.</p>
<p class="articleParagraph enarticleParagraph">Japanese doctors took the treatment a stage further by carrying out a live transplant, from a mother to her 27-year-old daughter. A section of the mother's pancreas was removed, the islet cells isolated and washed and infused into her daughter's liver, where they began functioning normally, producing insulin.</p>
<p class="articleParagraph enarticleParagraph">Scientists at Akron University in Ohio are experimenting with a "bio-artificial" pancreas - the size of a cigarette coated with a membrane that holds islet cells and promotes the exchange of insulin and glucose between the cells and the blood.</p>
<p class="articleParagraph enarticleParagraph">The Ovaries and Testes</p>
<p class="articleParagraph enarticleParagraph">The reproductive organs present unique problems. In men, sperm is produced profusely and continuously and can be easily frozen and stored.</p>
<p class="articleParagraph enarticleParagraph">Women, however, only produce one or two mature egg cells each month and their reproductive life ends at the menopause. On top of this, egg cells are difficult to freeze. For infertile men and women who cannot produce any sperm or eggs, there is the possibility of creating the sex cells - gametes - in the laboratory from skin cells. The idea is to use the skin cells to create cloned embryos by inserting the cell nucleus into donor egg cells that have had their own nucleus removed.</p>
<p class="articleParagraph enarticleParagraph">After extracting embryonic stem cells from the three-day-old cloned embryos, scientists hope to stimulate them with nutrients and messenger chemicals to develop into mature sperm or eggs which crucially have half the number of chromosomes as the skin cells from which they were derived. Several research groups have achieved this stage of successful "haploidisation" in animals and are hoping to do the same with human skin cells to produce viable sperm or eggs.</p>
<p class="articleParagraph enarticleParagraph">Muscle</p>
<p class="articleParagraph enarticleParagraph">Duchenne muscular dystrophy is caused by a person's inability to produce a muscle protein called dystrophin. Scientists know how to make healthy versions of the dystrophin gene, and hope to find ways of inserting it into the affected muscles, and thus getting these damaged cells to behave normally. Gene therapy research is also looking at ways of boosting muscle size and strength.</p>
<p>Document IND0000020081122e4bm0002r</p></div><br/><span></span><div  class="article enArticle"><p>
<div>Features</div>
<div id="hd" ><b class='enHeadline'>Cure in sight</b>
</div><div>164 words</div><div>29 September 2008</div><div>The Evening Chronicle, Newcastle</div><div>EVECHR</div><div>2</div><div>English</div><div>(c) 2008 The Newcastle Chronicle & Journal Ltd   </div>
</p>
<p class="articleParagraph enarticleParagraph">In association with the NHS</p>
<p class="articleParagraph enarticleParagraph">GENE therapy can restore vision to people with a severe form of inherited blindness, early trial results have shown.</p>
<p class="articleParagraph enarticleParagraph">The treatment had a dramatic effect on three young patients in their 20s, two of whom responded within days. Doctors injected a virus containing the corrective gene into one eye of each of the participants, who had suffered severe sight loss since childhood. After one month all three had experienced significant improvement. In each patient the treated eye was more sensitive to light, and its field of vision increased, allowing a wider area to be seen. The aim of the therapy was to replace a defective gene, RPE65, which plays an essential role in the retinoid cycle. The experimental therapy has previously restored the sight of dogs and mice. The doctors wrote in the journal Proceedings of the National Academy of Sciences: "These results demonstrate dramatic, albeit imperfect, recovery of rod and cone photoreceptor-based vision."</p>
<p>Document EVECHR0020080930e49t0003z</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>How treatment was pioneered at Moorfields</b>
</div><div>150 words</div><div>23 September 2008</div><div>The Daily Express</div><div>THEEXP</div><div>15</div><div>English</div><div>(c) 2008 Express Newspapers </div>
</p>
<p class="articleParagraph enarticleParagraph">BRITISH doctors have led the way in gene replacement therapy to restore sight.</p>
<p class="articleParagraph enarticleParagraph">Last year a medical team at Moorfields Eye Hospital in London carried out the first eye surgery using gene therapy.</p>
<p class="articleParagraph enarticleParagraph">The remarkable technique was the result of 15 years work by Professor Robin Ali, at the Institute of Ophthalmology at University College London.</p>
<p class="articleParagraph enarticleParagraph">The intricate operation was carried out on Robert Johnson, 23, from London.</p>
<p class="articleParagraph enarticleParagraph">The civil servant was born with the inherited Leber's congenital amaurosis and could only see outlines during the day and very little at night.</p>
<p class="articleParagraph enarticleParagraph">His sight was not restored, but Professor Ali said the US study gave "huge encouragement".</p>
<p class="articleParagraph enarticleParagraph">He said: "We can now begin to find out how much vision is restored by improving retinal sensitivity and whether results are better in children when we treat the whole retina using a high dose."</p>
<p>Document THEEXP0020080923e49n0001s</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>Blind will 'see' within few days of gene therapy</b>
</div><div class="author">By Jo Willey </div><div>424 words</div><div>23 September 2008</div><div>The Daily Express</div><div>THEEXP</div><div>15</div><div>English</div><div>(c) 2008 Express Newspapers </div>
</p>
<p class="articleParagraph enarticleParagraph">REVOLUTIONARY gene therapy can cure a severe form of inherited blindness in days, groundbreaking trials show.</p>
<p class="articleParagraph enarticleParagraph">Early results of the pioneering treatment, which transplants genes into the eye, produced dramatic results.</p>
<p class="articleParagraph enarticleParagraph">Experts believe the therapy could be ready for use within two y ears to treat people suffering from some inherited diseases of the retina - which affect 30,000 people in Britain.</p>
<p class="articleParagraph enarticleParagraph">Within three years, it could be ready for testing on people who suffer age-related macular degeneration, a common condition affecting 500,000 Britons.</p>
<p class="articleParagraph enarticleParagraph">Doctors in the latest US trial injected a virus containing a corrective gene into one eye of three patients in their 20s.</p>
<p class="articleParagraph enarticleParagraph">All three suffered from Leber's congenital amaurosis. One in 100,000 babies are born with the condition, and their sight starts to deteriorate rapidly from birth.</p>
<p class="articleParagraph enarticleParagraph">Many sufferers go blind when they are adults.</p>
<p class="articleParagraph enarticleParagraph">Two of the patients responded within days. And in just a month, all had improved significantly.</p>
<p class="articleParagraph enarticleParagraph">In each patient the treated eye was more sensitive to light and its field of vision increased, allowing a wider area to be "seen".</p>
<p class="articleParagraph enarticleParagraph">The trial picks up on pioneering surgery carried out by British eye specialists at London's world-famous Moorfields Eye Hospital last year.</p>
<p class="articleParagraph enarticleParagraph">Doctors aimed to replace a defective gene called RPE65, which plays an essential role in helping to turn light signals into nerve messages to the brain.</p>
<p class="articleParagraph enarticleParagraph">When this "retinoid cycle" breaks down, the faulty gene stops the retina from detecting light and sight fails.</p>
<p class="articleParagraph enarticleParagraph">Scientists at the Scheie Eye Institute at the University of Pennsylvania in Philadelphia, detected huge improvements to the retina's light-sensitive cone and rod cells after treatment.</p>
<p class="articleParagraph enarticleParagraph">Cone function - responsible for colour and daytime vision - increased up to 50-fold. Rods, which provide night vision, became as much as 63,000 times more effective.</p>
<p class="articleParagraph enarticleParagraph">Researchers wrote in the journal Proceedings of the National Academy of Sciences: "These results demonstrate dramatic, albeit imperfect, recovery of rod and cone photoreceptor-based vision after RPE65 gene therapy."</p>
<p class="articleParagraph enarticleParagraph">James Bainbridge, who led the Moorfields surgical team, hailed the results, saying: "They are important because they provide further evidence that gene therapy can improve vision in people with this form of LCA.</p>
<p class="articleParagraph enarticleParagraph">"They also confirm the prediction that the extent of improvement depends on the number of surviving target cells."</p>
<p class="articleParagraph enarticleParagraph">Barbara McLaughlan, of the Royal National Institute of Blind People, welcomed the research into a form of blindness for which there has been no treatment.</p>
<p>Document THEEXP0020080923e49n0001t</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>Fundraising for sight charity</b>
</div><div>250 words</div><div>4 August 2008</div><div>The Evening Chronicle, Newcastle</div><div>EVECHR</div><div>12</div><div>English</div><div>(c) 2008 The Newcastle Chronicle & Journal Ltd   </div>
</p>
<p class="articleParagraph enarticleParagraph">WORK to give more blind people the chance of sight has had another boost, thanks to Jessica Levison.</p>
<p class="articleParagraph enarticleParagraph">Jessica, three, of Hindmarsh Drive, Ashington, was born with Leber's congenital amaurosis (LCA), a rare genetic condition.</p>
<p class="articleParagraph enarticleParagraph">LCA appears in the first few months of life and causes loss of vision. There are no effective treatments.</p>
<p class="articleParagraph enarticleParagraph">Earlier this year, researchers from the UCL Institute of Ophthalmology and Moorfields Eye Hospital announced results of the world's first clinical trial to test a revolutionary gene therapy treatment for LCA. The results showed the treatment is safe and can improve sight.</p>
<p class="articleParagraph enarticleParagraph">The researchers' work was carried out with the help of funding from charity Fight For Sight.</p>
<p class="articleParagraph enarticleParagraph">By way of thanks for the hope they have brought Jessica and others, a fundraising disco was held in Ashington. Nearly £1,300 was raised for Fight For Sight.</p>
<p class="articleParagraph enarticleParagraph">And now more cash raised in Jessica's name is being handed to the charity. Danielle Hockley, a relative of Jessica, decided to organise her own fundraising effort with the help of partner Wayne Doyle and colleague Denise Coatman.</p>
<p class="articleParagraph enarticleParagraph">They organised a quiz and raffle, with prizes donated by their employer Currys, and a total of £403.54 was raised.</p>
<p class="articleParagraph enarticleParagraph">Danielle Hockley is cousin to Jessica's dad, Grahame Levison.</p>
<p class="articleParagraph enarticleParagraph">His mum, Debbie Levison, said: "They wanted to do something to help Jessica."</p>
<p class="articleParagraph enarticleParagraph">A cheque for the money raised from the quiz night is being sent to the Ashington branch of Currys.</p>
<p>Document EVECHR0020080804e48400007</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Charity sailor stops off in port</b>
</div><div>201 words</div><div>12 July 2008</div><div>Herald Express</div><div>HEREXP</div><div>default</div><div>17</div><div>English</div><div>(c) 2008 Herald Express   </div>
</p>
<p class="articleParagraph enarticleParagraph">The gradual blindness of his toddler godson persuaded sailor Mike Brooks to stage a fund-raising sail round the UK which brings him to Brixham harbour today.</p>
<p class="articleParagraph enarticleParagraph">His target is £27,000 to help pay for vital gene therapy research which will prevent other youngsters with the congenital condition from losing their sight and may lead to a cure for people like Theo Holroyd, 18 months.</p>
<p class="articleParagraph enarticleParagraph">Colonel Brooke, OBE, is due to arrive in his 19-foot Cape Cutter Theo's Future as part of his charity navigation of Britain's coastline.</p>
<p class="articleParagraph enarticleParagraph">The three-man crew will be sailing 1,500-nautical miles over three months to raise £27,000 for eye research charity, Fight for Sight.</p>
<p class="articleParagraph enarticleParagraph">The money will be used to purchase a vital piece of gene-screening equipment for researchers at the UCL Institute of Ophthalmology in London, and Moorfields Eye Hospital.</p>
<p class="articleParagraph enarticleParagraph">Col Brooke said: "These findings offer real hope of discovering a cure for Theo and others."</p>
<p class="articleParagraph enarticleParagraph">His trip is supported by Admiral Sir Sandy Woodward, celebrated naval commander in the Falklands War and international yachtsman Sir Robin Knox-Johnston.</p>
<p class="articleParagraph enarticleParagraph">For more information or to donate visit www.justgiving.com/theosfuture[http://www.justgiving.com/theosfuture]</p>
<p>Document HEREXP0020080715e47c0001w</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Voyage of discovery aims to help little Theo to see</b>
</div><div>372 words</div><div>10 July 2008</div><div>Chichester Observer</div><div>CHICOB</div><div>English</div><div>© 2008 Johnston Publishing Limited   </div>
</p>
<p class="articleParagraph enarticleParagraph">An ocean yacht master has begun a charity circumnavigation around Britain to fund vital research to help his tiny godson see the world for the very first time.</p>
<p class="articleParagraph enarticleParagraph">Colonel Mike Brooke left Bosham Quay on Saturday (July 5) aboard his 19ft boat Theo's Future, accompanied by a flotilla of up to 40 yachts and cheered from the quayside by hundreds of supporters, including Falklands naval commander Admiral Sir Sandy Woodward.</p>
<p class="articleParagraph enarticleParagraph">Col Brooke hopes his three-month 1,500-mile voyage of discovery aboard his three-man boat - which is named after his blind 18-month-old godson Theo Holroyd who suffers from Leber congenital amaurosis (LCA) - will raise £27,000 for eye research charity, Fight for Sight.</p>
<p class="articleParagraph enarticleParagraph">The charity will use the cash to fund a light scanner to help researchers find a cure for the inherited retinal disease that affects just one in 100,000 people.</p>
<p class="articleParagraph enarticleParagraph">"Theo is a wonderful little boy and an absolute joy to be around," said Col Brooke from Bosham.</p>
<p class="articleParagraph enarticleParagraph">"His family and friends want to do whatever it takes to help him to see and sailing around Great Britain is my way of helping. My goal is to raise £27,000 for Fight for Sight."</p>
<p class="articleParagraph enarticleParagraph">The exciting Caribbean-style launch party included a blessing of the vessel by Colonel Brooke's sister-in-law the Rev Jane Brooke, the vicar of Compstall, and it being officially named by his daughter-in-law Jayne Brooke.</p>
<p class="articleParagraph enarticleParagraph">The project to find a cure for little Theo is being scientifically led by Professor Tony Moore from Moorfields Eye Hospital.</p>
<p class="articleParagraph enarticleParagraph">He believes if he can track the ten genes to complete the vision link between the brain and retina, LCA sufferers will at last be able to see.</p>
<p class="articleParagraph enarticleParagraph">Col Brooke said: "The breakthrough is very exciting although a lot more work needs to be done before gene therapy will be available to treat Theo."</p>
<p class="articleParagraph enarticleParagraph">The sailor, who came ninth in last month's Round the Island race, will use the voyage to build links with institutions caring for partially-sighted and blind children including the West of England School and College for Children with Little or No Sight in Exeter.</p>
<p>Document CHICOB0020080711e47a00001</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>‘I’m going blind and my kids know they might, too’</b>
</div><div>962 words</div><div>4 July 2008</div><div>Belfast Telegraph</div><div>WBEL</div><div>English</div><div>(c)2008 Independent News & Media (Northern Ireland). All Rights Reserved.   </div>
</p>
<p class="articleParagraph enarticleParagraph">It must be one of the hardest things of all for an artist, to be losing her sight. But the Hon Mrs Sophie Montgomery, 43-year-old wife of Northern Irish newspaper magnate David Montgomery, and only daughter of Lord and Lady Birdwood, concentrates on the smaller, daily drawbacks. "One of the annoying things is that people will acknowledge me and I won't respond," she says. "They think they've been snubbed but it's simply because I haven't seen them. People put their hand out to shake mine and I don't see it. One just feels a bit vulnerable, you know?"She adds that she is now going public on her inherited complaint, retinitis pigmentosa (RP), which leads to blindness, as it saves embarrassment and raises awareness of this debilitating condition. "I don't want people thinking I'm drunk or rude," explains Sophie. "But the days of going out on my own at night, to parties or whatever, are numbered. I get disoriented if the light levels are low.</p>
<p class="articleParagraph enarticleParagraph"> I bump into people, knock trays over, fall down stairs."As well as the cost in terms of her social life and career, there is the cost to her as a mother. She has four children, three daughters — Olivia (18), Constance (16) and Claudia (12) — by her first marriage to the Earl of Woolton, and six-year-old William with Montgomery. "One day I won't be able to see my children's faces and I'll be unable to see my grandchildren." she acknowledges sadly. In fact, she took the risk that her fourth pregnancy would make her sight deteriorate since RP speeds up with pregnancy. But as she says, "It was a life-affirming thing. I knew what I was potentially risking but I really wanted a baby with David." And was her sight affected? "Yes, it was." Sophie knew there was a 50:50 chance she would suffer the same fate as her mother. "I had terrible night vision, and always wondered whether I might have it. I was aware that every year there was something else mummy found harder, but she was amazingly brave and was a history and English teacher until she was 50." Now 70, Lady Birdwood was registered blind four years ago.Two years after marrying David, Sophie noticed something was wrong: "People were coming up to me and I wasn't seeing them ..." Typically, RP causes a symptomatic roller-coaster, rather than a consistent decline. Sophie had her peripheral vision tested and the result was "completely abnormal". She copes but as her eyesight worsens — she holds her arms out two feet apart to indicate the limits of her detailed vision — daily life becomes increasingly fraught. Her son William's miniature cars litter the floor of her West London kitchen, causing problems. "Willie leaves his toys around and I'm always treading on them. He gets really angry. But I get cross with the children because they all leave things on the stairs and I fall over." Sophie must be undergoing an emotional rollercoaster too but uses the usual diversionary tactics, including dry humour. She tells herself she's lucky to have developed the condition late, as the onset of RP usually occurs between the ages of 10 and 30. But, of course, it's depressing and she admits to having down days. Sophie becomes emotional when discussing her mother's courage. "She's a very good role model," she says "The kids know they may develop RP but because she handles it so well, it alleviates a lot of fear for them. She gets frustrated but she's dignified."Talking to Louette Harding in You magazine, she adds: "I'm worried that the children are affected and I've noticed signs in a couple of them — so have they." Sophie reassures them with the fact that there's been something of a breakthrough with gene therapy.But it can't yet offer help to sufferers like Sophie, whose independence is dwindling. Could this affect her marriage? "I've thought about it. Do I fear it? Not at the moment, and he's been fantastically supportive. Contrary to what's said about him, Dave is actually quite a selfless person, although he's not a people-pleaser. But he hasn't really been put to the test yet. I mean, the level of care my father now gives my mother is enormous. It's something I can't really afford to worry about."The couple argue about leaving the lights on. "David keeps turning them off. He can't understand that if I turn off the lights, when I want to go back into that room I can't see where the light switch is." Maybe it's David's thrifty Ulster Presbyterian background coming to the fore? "Yes, absolutely."Sophie feels her role as a parent is compromised: "What really gets to me is when the older girls are out at night and I'm worrying and want to pick them up. I can't drive and do those maternal things."Her painting is already affected. Ironically, Sophie's work — bold abstracts and river scenes — has improved in the medium term. "Because of the ticking clock, I have an even greater motivation to paint," she says. Still, Sophie hasn't had her children tested. She adds: "I sincerely hope by the time any of the kids develop it, there will be a treatment for them, even if it simply inhibits the progress".To help the cause, Sophie and her father act as trustees of the British Retinitis Pigmentosa Society (www.brps.org.uk[http://www.brps.org.uk]), which funds research and helps sufferers</p>
<p>Document WBEL000020080704e4740000m</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>TRIALS BRING NEW HOPE</b>
</div><div>190 words</div><div>16 May 2008</div><div>The Evening Chronicle, Newcastle</div><div>EVECHR</div><div>9</div><div>English</div><div>(c) 2008 The Newcastle Chronicle & Journal Ltd   </div>
</p>
<p class="articleParagraph enarticleParagraph">TWO weeks ago researchers from the University College London Institute of Ophthalmology and Moorfields Eye Hospital NIHR Biomedical Research Centre announced results of the world's first clinical trial to test the revolutionary gene therapy treatment for LCA.</p>
<p class="articleParagraph enarticleParagraph">The results showed that the experimental treatment is safe and can improve sight.</p>
<p class="articleParagraph enarticleParagraph">LCA is a rare inherited eye disease caused by a gene abnormality. It causes progressive deterioration and loss of vision and there are currently no effective treatments available.</p>
<p class="articleParagraph enarticleParagraph">The purpose of the trial was to find out whether gene therapy for retinal disease is safe, and whether it can benefit vision in young adults who already have advanced retinal disease.</p>
<p class="articleParagraph enarticleParagraph">Following the treatment, the three patients involved all achieved levels of vision at least equivalent to before the operation, and one, Steven Howarth, had significantly improved night vision.</p>
<p class="articleParagraph enarticleParagraph">The team has now begun to try the technique for younger patients.</p>
<p class="articleParagraph enarticleParagraph">The team conducting the trial is led by Prof Robin Ali. He said: "These results give us great confidence that this technique is safe and can bring real benefit to those with impaired vision."</p>
<p>Document EVECHR0020080516e45g0000u</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>Light at the end of the tunnel for blind 3-year-old</b>
</div><div class="author">By VINCE GLEDHILL   </div><div>560 words</div><div>16 May 2008</div><div>The Evening Chronicle, Newcastle</div><div>EVECHR</div><div>9</div><div>English</div><div>(c) 2008 The Newcastle Chronicle & Journal Ltd   </div>
</p>
<p class="articleParagraph enarticleParagraph">MEDICAL BREAKTHROUGH MAY HOLD KEY TO YOUNGSTER'S SIGHT</p>
<p class="articleParagraph enarticleParagraph">SHE has spent her short life trapped in a world of darkness.</p>
<p class="articleParagraph enarticleParagraph">But now there is finally light at the end of the tunnel for youngster Jessica Levinson.</p>
<p class="articleParagraph enarticleParagraph">Three-year-old Jessica was born with a rare genetic condition that robbed her of sight.</p>
<p class="articleParagraph enarticleParagraph">But a breakthrough by medical researchers has now brought hope that Jessica may one day be able to see.</p>
<p class="articleParagraph enarticleParagraph">Just two weeks ago scientists working with Moorfields Eye Hospital in London announced that they had successfully carried out the world's first clinical trial to test a revolutionary gene therapy treatment for the inherited eye condition Leber's congenital amaurosis (LCA).</p>
<p class="articleParagraph enarticleParagraph">The youngest of three adults taking part in clinical trials, 18-year-old Steven Howarth, showed a remarkable improvement in his almost non-existent night vision, raising hopes that doctors may be on the right course towards a successful treatment for the condition.</p>
<p class="articleParagraph enarticleParagraph">Jessica who lives with her mum and grandparents at Hindmarsh Drive, Ashington, was born with LCA and has been to Moorfields for tests.</p>
<p class="articleParagraph enarticleParagraph">Doctors have not yet been able to identify the missing gene responsible for Jessica's LCA, but her family and friends are doing all they can to help the research. Next month they are holding a fundraising fancy dress disco to raise cash for the charity Fight For Sight, which is funding the research.</p>
<p class="articleParagraph enarticleParagraph">Jessica started attending classes at Hawthorn First School just over a week ago and the outgoing youngster is quickly making new friends.</p>
<p class="articleParagraph enarticleParagraph">Her family are now hoping that one day she will be able to see the faces of her new pals.</p>
<p class="articleParagraph enarticleParagraph">Her mum, Lindsey Smith, a 24-year-old student social worker, first became concerned when her daughter was three months old because she was not making eye contact with her. But after contacting her doctor was told that Jessica was probably just a slow developer.</p>
<p class="articleParagraph enarticleParagraph">She was six months old when it was confirmed that she was blind.</p>
<p class="articleParagraph enarticleParagraph">"It was a very traumatic and emotional time and it probably had a lot to do with me splitting up with her father. But the support I get now from the family and friends is fantastic.</p>
<p class="articleParagraph enarticleParagraph">"And Jessica is as bright as any other three-year-old.</p>
<p class="articleParagraph enarticleParagraph">"She never stops singing and she makes up stories all the time, and she absolutely loves The Spice Girls and Girls Aloud."</p>
<p class="articleParagraph enarticleParagraph">Jessica's special pal is three-year-old Dylan Baird, whose mum Janine is organising the fundraising disco along with Stacey Triplow.</p>
<p class="articleParagraph enarticleParagraph">The event will take place at the Elephant pub in Ashington on June 7 between 7pm and 11pm.</p>
<p class="articleParagraph enarticleParagraph">Mrs Baird and other friends set out to raise funds for the research supported by Fight For Sight and to help Jessica.</p>
<p class="articleParagraph enarticleParagraph">Ms Smith has been taking Jessica to Moorfields Eye Hospital for just over two years.</p>
<p class="articleParagraph enarticleParagraph">She said: "When I was down there the last time I was told that they had identified 12 genes that cause the condition, but none of them match the one that Jessica is missing."</p>
<p class="articleParagraph enarticleParagraph">To donate a prize or to find out more about the disco karaoke night contact Janine Baird on 07952 105 662 or Stacey Triplow on staceytriplow1984@hotmail.co.uk</p>
<p>Document EVECHR0020080516e45g0000t</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>Invention lets blind see again</b>
</div><div class="author">By Mark Stevenson   </div><div>451 words</div><div>11 May 2008</div><div>The Express on Sunday</div><div>THEXSU</div><div>16</div><div>English</div><div>(c) Copyright Express Newspapers 2008   </div>
</p>
<p class="articleParagraph enarticleParagraph">A CURE for hereditary blindness has been discovered thanks to revolutionary technology created by a Scottish eye-care company.</p>
<p class="articleParagraph enarticleParagraph">Scientists in the United States have hailed the device – made by Fife-based Optos – that can give detailed images from inside a patient's retina.</p>
<p class="articleParagraph enarticleParagraph">During clinical trials on three young adults with little or no sight the invention was crucial in a major breakthrough in treating congenital blindness, which up until now had no cure.</p>
<p class="articleParagraph enarticleParagraph">All three had their vision restored following operations at the Children's Hospital of Philadelphia.</p>
<p class="articleParagraph enarticleParagraph">Dr Eric Pierce, who carried out the procedure, said the Scottish device had been "a key tool".</p>
<p class="articleParagraph enarticleParagraph">He added: "The technology was used to collect widefield views of the retina and provided us with information which nothing else could.</p>
<p class="articleParagraph enarticleParagraph">This context of the disease could then be understood." There had previously been no treatment for the hereditary eye disease, called Leber's congenital amaurosis, which appears early in infancy and causes severe vision loss, especially at night.</p>
<p class="articleParagraph enarticleParagraph">Scientists used gene therapy and injected millions of copies of a working gene beneath the retina in the back of the eye of all three patients, two women aged 19 and 26, and a 26-year-old man.</p>
<p class="articleParagraph enarticleParagraph">The team relied on Optos' P200 device to provide digital images of the retina throughout the complicated procedure.</p>
<p class="articleParagraph enarticleParagraph">John McNeil, Optos company secretary, said yesterday: "Optos technology allows for potentially important new discoveries that may not have previously been fully appreciated due to limitations in existing imaging technology.</p>
<p class="articleParagraph enarticleParagraph">"Our device allows these doctors to capture this ultra-wide view of the retina." The breakthrough was revealed just days before Douglas Anderson, the founder of Optos, won the European Inventor of the Year award in Slovenia.</p>
<p class="articleParagraph enarticleParagraph">Mr Anderson, an industrial designer, had set to work on the invention after his fiveyear-old son Leif went blind in one eye because laborious and invasive traditional eye scans meant a detached retina was detected too late.</p>
<p class="articleParagraph enarticleParagraph">Doctors told him at the time how difficult it was to give small children a complicated and unpleasant eye check-up. So he took the problem back to his engineering firm, Crombie Anderson, vowing to find a thorough, painless way of checking eye problems.</p>
<p class="articleParagraph enarticleParagraph">The non-invasive test takes just a quarter of a second, using low-powered laser beams to create digital images of more than 80 per cent of the retina, compared with a scan of only five per cent possible under conventional check-ups.</p>
<p class="articleParagraph enarticleParagraph">The Optomap also does away with the need for dilation drops in the eye – and removes the distress of undergoing the original, less effective, and lengthier examination.</p>
<p>Document THEXSU0020080512e45b0001b</p></div><br/><span></span><div  class="article enArticle"><p>
<div>GH</div>
<div id="hd" ><b class='enHeadline'>SEEING IS BELIEVING FOR THE EYE-INJECTION BOY GIVING HOPE TO MILLIONS</b>
</div><div class="author">BY ISLA WHITCROFT   </div><div>1284 words</div><div>6 May 2008</div><div>Daily Mail</div><div>DAIM</div><div>47</div><div>English</div><div>(c) 2008 Associated Newspapers. All rights reserved   </div>
</p>
<p class="articleParagraph enarticleParagraph">AT A central London warehouse 18-year-old Steven Howarth is wandering around a specially constructed street scene in front of a group of eminent eye doctors and scientists.</p>
<p class="articleParagraph enarticleParagraph">It is dimly lit and Steven, who suffers from a genetic eye condition, has never been able to see in the dark. The last time he carried out this test he bumped into most objects in his path.</p>
<p class="articleParagraph enarticleParagraph">But now, almost a year on, everyone hopes things will be different. For Steven, a student from Bolton in Lancashire, is one of the first people in the world to have genetic therapy -- the replacement of a faulty gene with an artificially created one that works -- to try to improve his impaired sight.</p>
<p class="articleParagraph enarticleParagraph">Steven suffers from a form of Retinitis Pigmentosa called Leber's congenital amaurosis. This is an eye condition caused by a fault on the RPE 65 gene, which is responsible for the functioning of the retina, the lightdetecting layer at the back of the eye.</p>
<p class="articleParagraph enarticleParagraph">Since birth, Steven has had almost no night vision and his day vision was deteriorating to the point where he would probably be blind by his 20s.</p>
<p class="articleParagraph enarticleParagraph">Although the condition is genetic, there is no impaired vision in his family. Both his mother and father are one in 20,000 of the population who carry one half of the gene. Together, they had a one in four chance of having a child with the disease.</p>
<p class="articleParagraph enarticleParagraph">Steven has only peripheral vision and his central blind spot meant he couldn't see straight ahead or up and down.</p>
<p class="articleParagraph enarticleParagraph">As a youngster, he was continually tripping over. At primary school, he struggled to see the blackboard and at secondary school he was bullied because of his sight impairment.</p>
<p class="articleParagraph enarticleParagraph">teachers were sympathetic, but others just stuck me at the front of the class and, when that didn't work, they called me lazy,' he says.</p>
<p class="articleParagraph enarticleParagraph">But last July, Steven made medical history. He had an operation at Moorfields Eye Hospital in London, in which ophthalmic surgeon Mr James Bainbridge injected a healthy copy of the faulty gene into the central area of Steven's retina.</p>
<p class="articleParagraph enarticleParagraph">Under anaesthetic, a cannula containing the correct version of the gene was inserted into Steven's eyeball just above the iris and passed through the back of the eye into the retina.</p>
<p class="articleParagraph enarticleParagraph">Once in place, the gene, which is carried in a harmless virus, was injected in between the retina and the layer behind it, called the retinal pigment epithelium.</p>
<p class="articleParagraph enarticleParagraph">'A virus is a very efficient vehicle for getting to cells,' explains Robin Ali, professor of human molecular genetics at University College London, who ran the trial with Moorfields.</p>
<p class="articleParagraph enarticleParagraph">'Once injected, it quickly finds its way to the retinal cells. The new gene is then absorbed and, hopefully, overrides the natural genetic fault. Cells in the eye do not replicate, so once the RPE 65 gene is in place it should, in theory, stay put.'</p>
<p class="articleParagraph enarticleParagraph">'I could sense the doctor's excitement,' says Steven. 'I knew if my night vision improved there were huge implications for treating people with impaired sight.'</p>
<p class="articleParagraph enarticleParagraph">Corrupted genes are responsible for many severe eye conditions including Retinitis Pigmentosa (which affects around 24,000 people in the UK) and some forms of macular degeneration, which causes partial or total loss of sight in millions of people worldwide.</p>
<p class="articleParagraph enarticleParagraph">Not surprisingly then, eight months later as they watched Steven navigate the warehouse, the ophthalmic surgeons, geneticists and scientists were keen to witness the results.</p>
<p class="articleParagraph enarticleParagraph">The outcome was better than they had hoped for. Steven's negotiating skills in the dark were transformed and, as he finished the test, the results were conclusive. His night vision had improved 100-fold. The gene therapy had worked and it has transformed his life.</p>
<p class="articleParagraph enarticleParagraph">'Loss of vision means loss of independence,' says Steven, who is studying music at college. 'Before the operation, I had to rush home before it got dark, or I depend on other people.</p>
<p class="articleParagraph enarticleParagraph">'It wasn't too bad in familiar surroundings. I'd count the steps along the route from the local train station to our house, but I have fallen over or got lost so many times. Now I can see</p>
<p class="articleParagraph enarticleParagraph">cracks in the pavement and make out road signs. I feel free.'</p>
<p class="articleParagraph enarticleParagraph">Until he was eight, eye doctors at Bolton General Hospital had insisted that Steven was shortsighted and gave him thick glasses, which didn't work.</p>
<p class="articleParagraph enarticleParagraph">He was finally diagnosed with Retinitis Pigmentosa when he was eight (the diagnosis of Leber's congenital amaurosis came a few years later) when his mother, Adelaida, read an article on the condition, recognised the symptoms and took it to her doctor. For Adelaida, the diagnosis, although shattering, was a relief because it meant she could finally get help for her son.</p>
<p class="articleParagraph enarticleParagraph">Steven's father, Tommy, took him to be examined by a worldclass specialist at Moorfields Eye Hospital. 'He confirmed the diagnosis, that there was no cure,' says Tommy. 'That was a real blow.'</p>
<p class="articleParagraph enarticleParagraph">As Steven's sight deteriorated he could watch TV only if he sat close up, and he could read only large print books.</p>
<p class="articleParagraph enarticleParagraph">He was unable to play sport, which marked him out as different. 'School was tough,' he admits. 'I wanted to be like everyone else, but I had a tutor who sat next to me and read things out. I was bullied. I left at 16 with very poor GCSE results.'</p>
<p class="articleParagraph enarticleParagraph">Through the Retinitis Pigmentosa Society, Steven became aware of the progress in genetic therapy research into his condition, and 15 months ago, Moorfields</p>
<p class="articleParagraph enarticleParagraph">asked if he wanted to join the gene therapy trial.</p>
<p class="articleParagraph enarticleParagraph">'I was both excited and terrified,' he remembers. 'But we decided to find out more.'</p>
<p class="articleParagraph enarticleParagraph">In June 2007, Steven had two weeks of tests and interviews to see if he was suitable for the trial and made aware of the many possible dangers.</p>
<p class="articleParagraph enarticleParagraph">'There was a risk of haemorrhage, retinal tear or detachment,' says surgeon Mr Bainbridge. 'There was also a post-operative risk of inflammation and infection, that's why we operated on Steven's right eye -- if it went wrong he still had his best eye.'</p>
<p class="articleParagraph enarticleParagraph">there were the theoretical dangers of the genetic therapy. 'There was the tiny possibility that the gene might not stay in the retinal cells but travel around the body and alter the DNA,' says Professor Ali.</p>
<p class="articleParagraph enarticleParagraph">Finally, there was the possibility that the body's immune system would reject the new gene. To counteract this, Steven was given immuno suppressant drugs.</p>
<p class="articleParagraph enarticleParagraph">Steven was cleared for the operation. 'I was nervous but determined to go ahead,' he says. 'When I woke up my eye felt very sore and I had to take painkillers.</p>
<p class="articleParagraph enarticleParagraph">'At first my vision was incredibly blurred. The doctors had said it might take several months before my eye recovered, so I tried not to worry.</p>
<p class="articleParagraph enarticleParagraph">'By October, four months later, my vision had improved, but it was hard to tell how much.'</p>
<p class="articleParagraph enarticleParagraph">It wasn't until the follow-up test this March that he could tell how much better he was. 'I watched the before and after video of me navigating the dark street scene,' says Steven. 'It felt brilliant.'</p>
<p class="articleParagraph enarticleParagraph">As Steven was one of the first people in the world to have the procedure, he was given a low dose of the therapy and only one third of his retina was treated, so there is scope for improvement.</p>
<p class="articleParagraph enarticleParagraph">'I would like at some point to be considered for another dose, perhaps in my right eye,' he says. 'Ultimately, my dream is to have my vision restored to normal.'</p>
<p>Document DAIM000020080506e4560001r</p></div><br/><span></span><div  class="article enArticle"><p>
<div>COLUMNS</div>
<div id="hd" ><b class='enHeadline'>Society must see the bigger picture</b>
</div><div class="author">Ann WIDDECOMBE </div><div>194 words</div><div>30 April 2008</div><div>The Daily Express</div><div>THEEXP</div><div>13</div><div>English</div><div>(c) 2008 Express Newspapers </div>
</p>
<p class="articleParagraph enarticleParagraph">A NEW treatment for blindness in young people is a heartening development.</p>
<p class="articleParagraph enarticleParagraph">Trials of the gene therapy have transformed the lives of blind patients, such as Steven Howarth, above.</p>
<p class="articleParagraph enarticleParagraph">In David Blunkett's touching memoir of his early years, he recalled how children from his school for the blind used to climb trees and perform other daredevil feats, which would seem normal to the sighted but give any responsible adult a fit when carried out by a sightless child.</p>
<p class="articleParagraph enarticleParagraph">Yet that was an age when children were encouraged to take the odd risk and a fall from a tree's lower branches would have resulted in bruises rather than lawsuits. In this over-protective, compensation-obsessed age, even a game of conkers is a huge risk.</p>
<p class="articleParagraph enarticleParagraph">If blind children are given their sight by some wonderful new science, then that is terrific. But I hope they do not believe they will suddenly be able to become more adventurous, because all they will find is that their every move is regulated by a society so enslaved to the rulebook that it cannot see beyond its nose.</p>
<p>Document THEEXP0020080430e44u00014</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>ATEENAGER who got his sight back after a pioneering operation now plans to...</b>
</div><div class="author">CHRIS OSUH   </div><div>453 words</div><div>29 April 2008</div><div>Manchester Evening News</div><div>MN</div><div>English</div><div>(c) 2008   </div>
</p>
<p class="articleParagraph enarticleParagraph">ATEENAGER who got his sight back after a pioneering operation now plans to become a pop star.</p>
<p class="articleParagraph enarticleParagraph">Steven Howarth, a student at Wigan and Leigh College, suffers from a rare condition which meant he could not see anything in the dark.</p>
<p class="articleParagraph enarticleParagraph">He faced going completely blind in his 20s until doctors injected healthy genes into his right eye to dramatically improve his sight.</p>
<p class="articleParagraph enarticleParagraph">Steven, 18, of Westhoughton, said the operation had opened up a world of possibilities - including a music career.</p>
<p class="articleParagraph enarticleParagraph">He said: "Now I have more independence I'd love to play gigs with my band The Malinskys.</p>
<p class="articleParagraph enarticleParagraph">"I'd like to do a national diploma in music and then get a job.</p>
<p class="articleParagraph enarticleParagraph">"The thought I would go blind when I was older used to bring me down but now my life has changed."</p>
<p class="articleParagraph enarticleParagraph">The operation on Steven's eye means he can now make his own way back from visiting his girlfriend in Chorley and college pals in Wigan.</p>
<p class="articleParagraph enarticleParagraph">Steven's mum, Adelaida, said: "It's been difficult for Steven to get work because of his eye condition but hopefully it will be a lot easier now. He will never be able to drive but the improvement to his vision has given him much more freedom."</p>
<p class="articleParagraph enarticleParagraph">As reported in later editions of yesterday's M.E.N., Steven had the operation last July on his 18th birthday and his sight has been steadily improving ever since.</p>
<p class="articleParagraph enarticleParagraph">He was one of three people to have the operation at Moorfield Eye Hospital, in London, which involved doctors injecting healthy copies of genes into the retina. Of the three operations, Steven's was the most successful. Steven's genetic condition - Lebers Congenital Amaurosis - affects one in 100,000 people. It was not diagnosed until he was eight.</p>
<p class="articleParagraph enarticleParagraph">The teenager now hopes to have the sight in his left eye improved by the same procedure.</p>
<p class="articleParagraph enarticleParagraph">The government-funded trial was conducted by a team headed by Professor Robin Ali and includes eye surgeon James Bainbridge and retinal specialist Professor Tony Moore. Professor Ali has hailed the trial as a 'very significant milestone' which paves the way for the development of gene therapy approaches for a range of eye disorders. Adelaida added: "Steven has been a guinea pig - in a good way. I think the doctors at Moorfield have been absolutely fantastic.</p>
<p class="articleParagraph enarticleParagraph">"They put an incredible amount of time and effort into helping Steven."</p>
<p class="articleParagraph enarticleParagraph">chris.osuh@men-news.co.uk</p>
<p>WORLD OF POSSIBILITIES Steven Howarth's sight has steadily improved since his operation. HOW THEY DID IT Surgeons inserted healthy genes into Steven's retina to correct a genetic fault   </p>
<p>Document MN00000020080429e44t0001k</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Gene op saves sight of student</b>
</div><div>292 words</div><div>29 April 2008</div><div>Wigan Evening Post</div><div>WIGEVP</div><div>English</div><div>(c) 2008 Johnston Publishing Limited   </div>
</p>
<p class="articleParagraph enarticleParagraph">A music student at Wigan and Leigh College believes his sight will get "even better" after pioneering eye treatment.</p>
<p class="articleParagraph enarticleParagraph">Doctors at Moorfields Eye Hospital in London used gene therapy to regenerate the dying cells in Steven Howarth's right eye.</p>
<p class="articleParagraph enarticleParagraph">Before the procedure the 18-year-old, who is studying for a first diploma in performing arts, could hardly see at all at night and eventually would have lost his sight completely.</p>
<p class="articleParagraph enarticleParagraph">His condition, Lebers congenital amaurosis, was due to a faulty gene that meant that the light-detecting cells at the back of his eye were damaged and degenerating further.</p>
<p class="articleParagraph enarticleParagraph">Steven, from Westhoughton is one of the first three people to receive the treatment. Researchers implanted healthy copies of genes into his eye to restore activity in cells vital for vision.</p>
<p class="articleParagraph enarticleParagraph">Steve said: "Now, my sight when it's getting dark or it's badly lit is definitely better. It makes a big difference to me and it's still improving, so hopefully it will continue to get better -although I'm grateful for what they've done for me so far."</p>
<p class="articleParagraph enarticleParagraph">Guitarist Steve joined Wigan College band The Millinskys in September and revealed his musical abilities were influenced by his poor sight.</p>
<p class="articleParagraph enarticleParagraph">He said: "I used to stay at home pretty much all the time on a night so in that way it helped with my music."</p>
<p class="articleParagraph enarticleParagraph">Breakthrough gene therapy could improve the eyesight of hundreds of thousands of people who suffer from inherited blindness.</p>
<p class="articleParagraph enarticleParagraph">Known as Leber's congenital amaurosis (LCA), the inherited disorder causes progressive deterioration in vision and can lead to blindness in teenagers.</p>
<p class="articleParagraph enarticleParagraph">It occurs when faulty genes stop the layer of cells at the back of the eye working.</p>
<p>Document WIGEVP0020080429e44t00002</p></div><br/><span></span><div id="lastArticle"  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Gene trial helps teen see again; Gene-eye-use: a very happy Steven Howarth</b>
</div><div>169 words</div><div>29 April 2008</div><div>Metro</div><div>METRO</div><div>DUBA</div><div>3</div><div>English</div><div>(c) 2008 Associated Newspapers. All rights reserved.   </div>
</p>
<p class="articleParagraph enarticleParagraph">A TEENAGER who was losing his sight has been helped by a breakthrough in gene therapy. Working genes were injected into one of 18-year-old Steven Howarths eyes to correct a genetic fault that was stopping his retinas detecting light properly. As a result of the treatment partially funded by Irish charity Fighting Blindness his vision improved significantly. At first, I could not see anything, really, in the eye that was operated on, but it got much better after a week, then gradually even better until it was back to normal, said Mr Howarth, from Bolton, UK. The trial is a very significant milestone, said Prof Robin Ali, who led the UK arm of the British and American work on six volunteers. This trial establishes proof of principle of gene therapy for inherited retinal disease, and paves the way for the development of gene therapy approaches for a broad range of eye disorders.</p>
<p>ASSCMMGLSTRY000019836084</p>
<p>Document METRO00020080429e44t0005w</p></div><br/></div></div><span><div id="pageFooter"><table width="100%" cellspacing="0" cellpadding="0" border="0" class="footerBG">
	<tr>
		<td nowrap="nowrap" width="100%" align="right"><span class="copyright">&copy; 2011 Factiva, Inc.  All rights reserved.</span></td>
		<td><div class="ftright">&nbsp;</div></td>
	</tr>
</table>
<span class='shadowL'></span><span class='shadowR'></span></div></span></form><script type='text/javascript'>framesViewNotReqd = false;modalEnabled = true;modalPopupIframeDefaultSource='/blank.htm';RequestFromModal=false;RequestFromIPad=false;</script>
</body>
</html>